version 1.[ADDRESS_955668]. Tom Lietman  
1 | Page 
 
 Mortality Reduction After  
Oral Azithromycin  
 
Manual of Operations and Procedures  
 
The Francis I. Proctor Foundation, Global Health Sciences  
University of [LOCATION_004], San Francisco  
The Carter Center 
Niger Ministry of Health  
 
The Dana Center, Bloomberg Schoo l of Public Health  
Johns Hopkins University  
Tanzania National Institute for Medical Research and Muhimbili Medical 
Center 
 
The London School of Hygiene & Tropi[INVESTIGATOR_703812], University of Malawi, Blantyre  
Malawi Ministry of Health  
 
MORDOR Study  
Manual of Operations and Procedures   [CONTACT_73126]  
2 | Page 
 Tabl e of Contents  
ABBREVIATIONS  ....................................................................................................................................... 5  
CHAPTER 1: OVERVIEW  ............................................................................................................................ 6  
1.1. EXECUTIVE SUMMARY  ....................................................................................................................... 6  
1.2. OBJECTIVES  ..................................................................................................................................... 6  
1.3. STUDY SITES .................................................................................................................................... 7  
CHAPTER 2: CONTEXT  ...................................................................................................................... 7  
CHAPTER 3: STUDY DES IGN  ......................................................................................................... 10 
3.1. RANDOMIZATION  ........................................................................................................................... 11 
CHAPTER 4: STU DY ELIGIBILITY  ................................................................................................. 11 
4.1. ELIGIBLE COMMUNITIES  ................................................................................................................... 11 
4.2. ELIGIBLE INDIVIDUALS ...................................................................................................................... 12 
4.3. STUDY SCHEDULE  ........................................................................................................................... 13 
CHAPTER 5: CORE AND NON- CORE STUDY ELEMENTS  ....................................................... 14 
5.1. MORTALITY STUDY  ......................................................................................................................... 14 
5.1.1.  Core Elements (Malawi, Niger, and Tanzania)  ............................................................. 14 
5.2. MORBIDITY /RESISTANCE STUDY  ........................................................................................................ 15 
5.2.1.  Core Elements (Malawi, Niger, and Tanzania)  ............................................................. 15 
5.2.2.  Non- core Elements  ............................................................................................................. 15 
CHAPTER 6:  CENSUS ...................................................................................................................... 16 
6.1. CENSUS  ........................................................................................................................................ 16 
6.2. RANDOM CENSUS VERIFICATION  ....................................................................................................... 18 
6.3. VERBAL AUTOPSY  .................................................................................................................... 19 
6.4. VALIDATING THE MORTAL ITY OUTCOME  .............................................................................. 20 
6.4.1 Niger  .......................................................................................................................................... 20 
6.4.2 Malawi  ..................................................................................................................................... 21 
6.4.3 Tanzania  ................................................................................................................................... 22 
CHAPTER 7: REGISTERI NG PARTICIPANTS FOR SPECIMEN COLLECTION  .................... 22 
CHAPTER 8: BLOOD SAM PLES ..................................................................................................... [ADDRESS_955669] ................................................................................................................. 26 
8.4. THICK AND THIN SMEARS FOR MALARIA  ............................................................................. 27 
8.5. MATERIALS FOR BLOOD COLLECTION  .................................................................................................. 28 
CHAPTER 9: SPECIMEN COLLECTION FOR RESISTANCE TESTI NG ................................... [ADDRESS_955670]. Tom Lietman  
3 | Page 
 CHAPTER 10: COST -EFFECTIVENESS  .......................................................................................... 35 
10.1.  COSTS .......................................................................................................................................... 35 
10.2 EFFECTIVENESS  .............................................................................................................................. 35 
CHAPTER 11: TRAINING  ................................................................................................................ 36 
11.1 STANDARDIZATION  ......................................................................................................................... 36 
11.2 PI[INVESTIGATOR_73034]  ............................................................................................................................... 36 
CHAPTER 12: SAMPLE O RGANIZATION, TRANSPORT, AND STORAGE  .......................... 37 
12.1 DE-IDENTIFICATION  ......................................................................................................................... 37 
12.2 SPECIMEN TRANSPORT  ........................................................................................................... 37 
12.3 SPECIMEN STORAGE  ................................................................................................................ 38 
12.3.1  Short -term Sample Storage  ......................................................................................... 38 
12.3.2  Long -term Sample Storage  .......................................................................................... 38 
12.4 CATALOG SPECIMENS  ............................................................................................................. 38 
CHAPTER 13: MICROBIO LOGY AND MOLECULAR LABORATORY PROCEDURES  ........ 39 
13.1 STORAGE AND TRANSPORT MEDIA  ....................................................................................... 39 
13.1.1  Preparation of STGG Transport Medium  ................................................................. 39 
13.1.2  Preparation of Amies Transport Medium  ................................................................. 40 
13.1.3  Preparation of Nutrient Agar Medium/Slants  ......................................................... 41 
13.2 METHO DS FOR MALARIA TESTING  ........................................................................................ 42 
13.2.1  Blood Smears  ................................................................................................................. 42 
13.2.2  Dried Blood Spots  ......................................................................................................... 42 
13.3 METHODS FOR RESISTANCE TESTING  ................................................................................... 48 
13.3.1  Isolation & Identification of Organisms Using Microbiological Techniques  ..... 48 
13.3.2  Microbiological Resistance Testing for Swabs  ........................................................ 50 
13.3.3  Nucleic Acid Based Resistance Testing for Stool Specimens .................................. 52 
13.4 METHODS FOR CHLAMYDIA TRACHOMATIS  (NON -CORE )...................................................... [ADDRESS_955671] es for PCR  ................................................................................... 54 
13.4.3  Procedure for Masking Samples  ................................................................................. 54 
13.4.4  Procedure for Pooling Samples  ................................................................................... 55 
13.4.5  Quality Control  ............................................................................................................ 55 
13.4.6  Quantification  ............................................................................................................... 55 
CHAPTER 14: STUDY ME DICATION  ............................................................................................ 56 
14.1  STUDY MEDICATION DESCRIPTION (FROM PFIZER , INC.) ............................................................................... 56 
14.1 DOSAGE INFORMATION  ................................................................................................................... 56 
14.2 MEDICATION PROCUREMENT /DONATION  ........................................................................................... 56 
14.3 MEDICATION QUALITY CONTROL  ....................................................................................................... 57 
14.4 ANTIBIOTIC DISTRIBUTION & MONITORING COVERA GE.......................................................................... 57 
14.5 ADVERSE REACTIONS /SIDE EFFECTS  ................................................................................................... 57 
14.6 ADVERSE EVENTS SYSTEMS  ............................................................................................................... 58 
14.6.1  Passive Adverse Events Monitoring  .......................................................................... 58 
14.6.2  Active Adverse Events Monitoring  ............................................................................ 58 
14.6.3  Adverse Events Data  .................................................................................................... 60 
14.8   SUPPLY ISSUES  ..................................................................................................................................... 60 
CHAPTER 15: PROTECTI ON OF HUMAN SUBJECTS  ................................................................ [ADDRESS_955672]. Tom Lietman  
4 | Page 
 15.1.1.  Niger ................................................................................................................................ 61 
15.1.2  Tanzania  ........................................................................................................................ 62 
15.1.3  Malawi  ........................................................................................................................... 62 
15.2 INFORMED CONSENT  ....................................................................................................................... 62 
15.3 RISKS AND BENEFITS OF STUDY PROCEDURES  ....................................................................................... 63 
15.3.1  Verbal Autopsy  .............................................................................................................. 63 
15.3.2  Swabbing Procedures  ................................................................................................... 63 
15.3.3  Stool Collection  ............................................................................................................ 63 
15.3.4  Blood Testing  ................................................................................................................. 63 
15.3.5  Anthropometric Measurements  .................................................................................. 63 
CHA PTER 16: STUDY MONITORING  ........................................................................................... 64 
CHAPTER 17: DATA AND  SAFETY MONITORING COMMITTEE CHARTER  ..................... [ADDRESS_955673] INFORMATION  ....................................................................................................... 68 
CHAPTER 18: DATA COLLECTION, MANAGEMENT,  AND SECURITY  ............................... [ADDRESS_955674]. Tom Lietman  
5 | Page 
 Abbreviations  
 
DCC: Data Coordinating Center  
GPS: g lobal p ositioning s ystem  
IRB: Institutional Review Board 
JHU: The Johns Hopkins Univ ersity  
LSHTM: London School of Hygiene and Tropi[INVESTIGATOR_703813]: mid -upper arm circumference  
NP swabs: nasopharyngeal swabs  
PCR: p olymerase chain r eaction  
STGG: skim milk tryptone glucose glycerin media  
UCSF: University of [LOCATION_004] San Francisco  WHO: World Health Organization  
MORDOR Study  
Manual of Operations and Procedures   [CONTACT_73126]  
6 | Page 
 Chapter 1: Overview 
 
1.1. Executive Summary  
An estimated 7.[ADDRESS_955675] will be seen in areas not eligible for trachoma treat ments. If mass 
azithromycin can be proven to reduce childhood mortality, then widespread 
implementation in developi[INVESTIGATOR_73036].  
 Our long- term goal is to more precisely define the role of mass azithromycin 
treatments as an intervention for reducing childhood morbidity and mortality. We propose a multi- site, cluster -randomized trial comparing communities 
randomized to oral azithromycin with those randomized to placebo. To assess the generali zability of the intervention, we will monitor for antibiotic resistance, 
which could potentially limit adoption of mass antibiotic treatments. We will also begin to investigate possible explanatory factors for mortality reduction by 
[CONTACT_73067]. We hypothesize 
that mass azithromycin treatments will reduce childhood mortality even in areas with low trachoma prevalence, and will be accompanied by [CONTACT_703831].  
 
1.2. Objectives  
 
1: To test the hypothesis that mass distributions of oral azithromycin 
targeted to 1 -60 month old children reduces childhood mortality, in a 
cluster -randomized trial 
 2: To assess the cost -effectiveness of mass azithromycin in reducing 
childhood mortality  
 
3: To investigate the most plausible factors that could explain an effect of 
mass azithromycin on childhood mortality  
 
4: To assess for emergent macrolide resistance among children following 
mass azithromycin treatments  
MORDOR Study  
Manual of Operations and Procedures   [CONTACT_73126]  
7 | Page 
 5: To collect and securely store s amples from the nasopharynx, nares, 
conjunctiva, blood, and stool after azithromycin distributions to assess 
infectious burden and resistance  
 
Ancillary Aim 1  (non- core ): To assess the effect of mass azithromycin 
treatments on microbial diversity in the conjunctival, nasopharyngeal, 
nasal, and intestinal biome of children  
 
1.3. Study Sites  
A consortium of experienced researchers and program implementers will 
conduct the study in 3 sites ( Malawi, Niger,  and  Tanzania), chosen for diversity 
of geography and comorbidities, existence of a functioning national azithromycin distribution program, and previous investigator experience:  
• Southern Africa:  Mangochi district, Malawi (Malawi Ministry of Health, 
University of Malawi, Blantyre, and London School of Hygiene & Tropi [INVESTIGATOR_703814])  
• West Africa: Loga and Boboye departments, Niger (Carter Center Niger, Niger Ministry of Health, University of [LOCATION_004], San Francisco)  
• East Africa:  Kilosa and Gairo district s, Tanzania ( National Institute for 
Medical Research, Kilosa , Johns  Hopkins University)  
Chapter 2: Context  
Reduction of childhood mortality is an international development goal.  The 
United Nations Millennium Development Goals call for a two -thirds reduction in 
childhood mortality by 2015.[ADDRESS_955676], three -quarters of all childhood deaths occur after 
the neonatal period, with malaria, pneumonia, and diar rhea accounting for the 
majority.7 Management is often case detection and individualized therapy, but 
novel strategies such as mass treatment may play a role.8-10  
 
The proposed research will assess whether childhood mortality can be reduced 
using a novel approach—mass antibiotic administrations similar to those used 
for tra choma.  The W orld H ealth Organization (WHO) recommends repeated 
annual distribution of single -dose oral azithromycin to each resident of 
trachoma -endemic communities, though more frequent treatments may be 
necessary.11-[ADDRESS_955677] been shown to be effective for these non -
chlamydial infections. For example, in a  study we conducted in Nepal, the 
prevalence of diarrhea in children decreased from 32% before a mass 
MORDOR Study  
Manual of Operations and Procedures   [CONTACT_73126]  
8 | Page 
 azithromycin treatment, to 11% ten days post -treatment (OR 0.26 [95% CI 0.14 – 
0.43]).[ADDRESS_955678] found that malaria parasitemia decreased 
by 44% after mass azithromycin treatments.[ADDRESS_955679].22 In a trial in Ethiopia, quarterly mass azithromycin treatments 
targeted to children aged 1 -10 years resulted in a 47% reduction in ocular 
chlamydia in untreated  community members.[ADDRESS_955680]. Tom Lietman  
9 | Page 
 are simple interventions and considerable expertise in their deployment already 
exists in developi[INVESTIGATOR_14696].[ADDRESS_955681] high childhood mortality, with a majority of programs achieving the targeted 70% coverage.
[ADDRESS_955682] proven to be sustainable; excluding the cost of the antibiotic itself, 
mass distribution costs an estimated $0.[ADDRESS_955683]. Tom Lietman  
10 | Page 
 Chapter 3: Study Design  
We will assess childhood mortality over two years, comparing communities 
where children aged  1-60 months receive biannual oral azithromycin (“Azithro” 
arm), to communities where the children receive biannual oral placebo (“Control” arm). We will also  randomize a separate set of communities to these 
treatment strategies , but monitor instead for in fectious disease morbidity and 
macrolide resistance  (“Azithro -Plus" and "Control -Plus”). These communities 
will not be included in the mortality comparison, since identification and 
treatment of morbidities could interfere with any mortality effect of 
azithromycin. All biologic specimens collected as part of the morbidity and 
resistance outcomes will be stored and made available to other investigators for further laboratory testing at the conclusion of the study, per Gates Fou ndation 
guidelines . 
 
Figure 1: Trial Profile  
     N + 30 communities   
            
           
   MORTALITY  
N communities   MORBIDITY/RESISTANCE  
30 communities  
             
   Azithro   Control                                      Azithro -Plus   Control -Plus   TREATMENT  
  Biannual  
mass  oral 
azithromycin 
to children  
  Biannual 
mass 
oral placebo 
to children   Biannual  
mass oral 
azithromycin to 
children   Biannual mass  
oral placebo to 
children   
N/2   
communities   N/2 
communities  15 
communities   15  
Communities    
            MONITORI NG 
  Every 6 months:  
• Census (births, 
deaths,  pregnancies,  
migration)  
• Verbal Autopsy 
(cause of death)  
• Costs of census and treatments   Every 12 months : 
• Blood smears, blood spots, 
and hemoglobin  
• Nasopharyngeal swabs  
• Nares swabs  
• Stool samples or rectal swabs  
• Conjunctival swabs  
• Anthropometry  
 
MORDOR Study  
Manual of Operations and Procedures   [CONTACT_73126]  
11 | Page 
  
3.1. Randomization  
 
Randomization of Treatment Allocation.  In each site, communities within a 
contiguous area of 300,[ADDRESS_955684] -efficient, 
morbidity studies . Since mortality and morbidity study communities will be 
drawn from the same pool, findings from one study will be relevant to the other. Each site has a different set of prevalent co -morbidities and different access to 
health interventions.  
 
No stratification or block randomization is planned within each country. The 
allocation of community assignments will be conducted for each country 
separ ately using simple random sampling. For each country, all study arms 
(mortality and morbidity) will be assigned from the same list of eligible 
communities. A pseudorandom number scheme will be implemented using the 
statistics package R. Randomization will be conducted by T. Porco. Procedural 
and algorithmic details are provided in an appendix to the Statistical Analysis Plan.  
 
Study Participants: At months 0, 12, and 24, a random sample of children will be 
selected using a computer -generated simple random sample for exams and 
sample collection to monitor for morbidity and resistance.   
Chapter 4: Study Eligibility   
 
4.1. Eligible Communitie s 
To be eligible for the trial, a community must meet the following criteria:  
 
1. The community location  in target district . 
2. The community leader consents to participation in the trial (this does 
not obviate the need for individual consent, but without overall leadership consent, the community as a whole cannot be part of the 
trial) .  
3. Eligible communities estimated population of be tween 200–2,[ADDRESS_955685]. Tom Lietman  
12 | Page 
 4.2. Eligible Individuals  
 
Mortality Study:  
Census: The study can be thought of as consisting of four 6 -month 
segments, each of which starts with a census and ends with a follow- up 
census. All ch ildren in the study communities aged 1 -60 months (up to but 
not including the 5th birthday) at the initial census of each segment are 
eligible to participate in the subsequent 6 -month segment of the study. 
Note that the information for children erroneously entered into the census 
(e.g., children young er than 1 month or ≥ 60months) can be corrected at 
the subsequent treatment, subsequent census, or at a verbal autopsy later in the study. However, these changes will not be applied retroactively; these misclassified children will still be included in the study population for that [ADDRESS_955686] udy drug.  
 
Treatment: Individuals allergic to macrolides or azalides w ill not be given 
the study antibiotic azithromycin , but will be included in the outcome.    
 
Morbidity/Resistance Study:  
 
Census: The criteria for being included in the census are the sa me as the 
Mortality Study, as described above.  
 
Treatment: The inclusion and exclusion criteria for treatment are the same 
as for the Mortality Study, as described above.  
 
Examination & Sample Collection: A random sample of children aged 1 -
60 months (up to  but not including the 5
th birthday) are eligible for 
examination and sample collection. As described above, the random sample will be a simple random sample based on the previous census. 
These individuals will likewise be selected from the previous census . 
 
 
 
 Note: All individuals must be registered on the official   
census in order to be considered part of the study.  
MORDOR Study  
Manual of Operations and Procedures   [CONTACT_73126]  
13 | Page 
  
4.3. Study Schedule  
The schedule for examination and treatment is shown below in Table 1:  
MORDOR Study Schedule  
   MORTALITY  MORBIDITY / RESISTANCE  
Azithro  Control  Azithro -Plus  Control -Plus  
Oral 
Azithromycin  
(N/2 
communities)  Oral Placebo        
(N/2 
communities)  Oral Azithromycin  
(N = 15 communities)  Oral Placebo    
(N = 15 communities)  
MORDOR 0  
Jan-15 to Jul -
15* Census  
Azithro Census  
Placebo  Census  
Swabs  
Blood  
Stool  
Anthropometry  
Azithro  Census  
Swabs  
Blood  
Stool  
Anthropometry  
Placebo  
MORDOR 6  
Aug-15 to 
Jan-16 
 Census  
Verbal Autopsy 
Azithro Census  
Verbal Autopsy 
Placebo  Census  
Azithro 
NP Swabs, Blood, Stool a 
Malaria Collectionb Census  
Placebo  
NP Swabs, Blood, Stool a 
Malaria Collectionb 
MORDOR 12  
Feb-16 to Jul -
16 Census  
Verbal Autopsy 
Azithro Census  
Verbal Autopsy  
Placebo  Census  
Swabs  
Blood  
Stool  
Anthropometry  
Azithro  Census  
Swabs  
Blood  
Stool  
Anthropometry  
Placebo  
MORDOR 18  
Aug-16 to 
Jan-17 Census  
Verbal Autopsy 
Azithro Census  
Verbal Autopsy 
Placebo  Census  
Azithro 
NP Swabs, Blood, Stool a Census  
Placebo  
NP S wabs, Blood, Stool a 
MORDOR 24  
Feb-17 to Jul -
17 Census  
Verbal Autopsy 
Azithroc Census  
Verbal Autopsy 
Azithroc Census  
Swabs  
Blood  
Stool  
Anthropometry  
Azithroc Census  
Swabs  
Blood  
Stool  
Anthropometry  
Azithroc 
Only children aged 1 month to 60 months per com munity will be treated  
Arms Azithro+ & Control+: swabs, blood testing, and stool samples or rectal swabs from 40 randomly selected children aged   
60 months per community; anthropometry from a cohort of children aged 1 to 60 months per community ; NP swa bs from 40 
individuals aged 7 – 12 years (Niger only)  
 
a: Tanzania only  
b: Niger only  
c: Decision to treat ALL communities with azithromycin at 24- months i f there is a significant mortality difference (in 
preparation for possible contingent study, Niger only)  
*: +/- [ADDRESS_955687]. Tom Lietman  
14 | Page 
 
 Chapter 5: Core and Non-Core Study Elements  
An overview of core and non- core elements for the mortality and morbidity study is 
provided here, but will be described in more detail in the following chapters.  
5.1. Mort ality Study  
 
5.1.1. Core  Elements (Malawi, Niger, and Tanzania)  
In all three study sites, we will conduct the following study activities for the 
mortality study:  
Training  
Before the baseline visit, the University of [LOCATION_004] San Francisco (UCSF) team will certify local team members at all three study sites. Standardization activities before 
each biannual census will consist of didactic classroom instruction and mock census 
activities, followed by [INVESTIGATOR_2993] -field training  to harmonize protocols.  
Census  
An enumerated  population census for 0 – 60 month olds (focusing on this age group) 
will be conducted every 6 months by [CONTACT_73069], 
recording births, deaths, and migration of children eligible for treatment.  Pregnant 
women will be noted at ea ch census, to maximize inclu sion of  newborns on the 
subsequent census.  
Random Census Verification  
A repeat census will be conducted   in a random selection of households at 
each study visit. Personnel will be different from the original census. This will allow us to assess whether the census team identified all births, deaths, and 
migratory epi[INVESTIGATOR_73038].  
Verbal Autopsy  
Each of the study sites will perform a  verbal autopsy for all children (aged 1 -60 
months) identified as having died during the study .
39  
Treatment  
Children aged 1 -60 months on the current census will be offered weight - or height -
based  (<1 year weight and children who cannot stand; ≥1 year  height) , directly 
observed, oral azithromycin suspension (or oral placebo) every [ADDRESS_955688]. Tom Lietman  
15 | Page 
 Antibiotic Coverage Surveillance  
We will estimate antibiotic coverage from the most recent biannual census 
records. At the end of each treatment round  at months 6, 12, and 18, we will 
identify any children who have missed [ADDRESS_955689] this information to the census team.  
5.2. Morbidity /Resistance  Study  
 
5.2.1. Core Elements (Malawi, Niger, and Tanzania)  
 
All core elements described in 5.1.1 will also be conducted in the morbidity  / 
resistance study.  The  enumerated population census for the 
morbidity/resistance communities will include 0 -12 year olds.   
 The designation “core elements” means that all study sites will be performing 
the study activity.  
 In all study sites, we will perform the following tes ts on a random sample of 40 
children aged 1 -60 months from each Azithro -Plus and Control -Plus community 
at baseline, 12, and 24 months:  
- Blood samples (dried blood spots optional) for malaria and anemia 
- Nasopharyngeal swabs for pneumococcal macrolide resistance  
- Stool samples or rectal swabs to assess for macrolide resistance  
- Assessment of costs of a census and mass drug administration (at 6 or 12 and 24 month visits  only)  
 Samples will be processed in -country when possible; otherwise they will be 
shipped to  UCSF . 
 
5.2.2. Non -core Elements  
The designation “non- core” element means that study sites may choose if they 
wish to perform the study activity. If the study sites perform the study activity, 
the methodology will be performed according to this protocol so that the 3 sites 
may be more easily compared. Sites may choose to perform several non -core 
morbidity assessments at the 0, 12, and 24 month visits: 
- Nasal swabs for macrolide resistance in Staphylococcus aureus  
- Conjunctival swabs for Chlamydia trachomatis  
- Conjunc tival examination and photography to assess for trachoma  
- Anthropometric assessments  
- Nasopharyngeal swab collection at local health posts to compare macrolide resistance in the community with that in the health post 
 
MORDOR Study  
Manual of Operations and Procedures   [CONTACT_73126]  
16 | Page 
 In addition, there are several non -core activities that occur outside the annual 
morbidity/resistance assessment:  
- Additional study visit during the first malaria season to collect blood 
samples for malaria and anemia testing  
- Clinic -based case finding for childhood illnesses at all health clinics  in the 
study area  
 
Costs  
We anticipate recording the cost of distributions in a random subset of 12 villages at 
the 6 or 12 and 24 month visits. 
Details of the non -core elements for each study s ite can be found in the 
Appendices . 
 
Chapter 6:  Census  
6.1. Cens us 
Census Team 
Census workers will be selected by [CONTACT_73070]. These individuals 
may have different qualifications and educational backgrounds in the [ADDRESS_955690].  Census 
workers will ideally be local community dwellers, and familiar with the communities being enumerated . In addition, several supervisors will be present 
for the duration of the census to monitor  census workers.  
 
Census Training  
Census workers will be trained at the beginning of the study and refresher 
trainings will be offered as needed for the duration of the study. Training will 
start with  reviewing the census data collection softwa re on the tablet computer, 
care of the tablets, charging of the tablets, etc. The training will then proceed to a demonstration of the use of the software at a mock household, including 
common problems that staff may encounter (e.g., no one at home, GPS fu nction 
not working, software crashing). In the final part of the training, the study 
coordinators and investigators will accompany team members to several communities and observe the census activities.  
 
Census Softwar e  
The census will be directly entered  into a tablet computer. The software will 
capture information about each child aged 0 -5 (or 0 -12 in morbidity 
communities) in each household: name, age, sex, father’s name, and mother’s 
name, and will also register any pregnant women. The GPS coordinates will be 
MORDOR Study  
Manual of Operations and Procedures   [CONTACT_73126]  
17 | Page 
 documented for each household at the entrance to the household. At follow -up 
censuses, team members will identify each household on the existing census, and 
will update the status for each child :  
- STATUS: Alive, slept in household last night  
- STATUS : Alive, but not in household  
o ABSENCE: <1 month  
 Is he/she coming back within 1 week?  
• Yes (mop -up) 
• No 
• I don’t know  
 INFORMANT: household member, neighbor, village chief, 
other  
o ABSENCE: ≥ 1 month  
 MOVE: Moved within community 
• INFORMANT : household member, neigh bor, village 
chief, other  
 MOVE: Moved outside of community 
• INFORMANT: household member, neighbor, village chief, other  
- STATUS: Died  
o PLACE: Child living in community when died 
 INFORMANT: household member, neighbor, village chief, other  
o PLACE: Child had move d out of community when died  
 INFORMANT: household member, neighbor, village chief, other  
- STATUS: Unknown  
o INFORMANT: household member, neighbor, village chief, other  
  Whenever a new individual is added to the census , the software will 
automatically assign each individual to a universal unique identification number 
as well as a study identification number.  
 
Census Data Uploading  
The census will be collected on tablet computers with 3G mobile and Wi- Fi 
capabilities. There will be [ADDRESS_955691] with data plan can be purchased  for each tablet , 
and the data uploaded via cell towers twice per day (midday and at the end of 
the day). This option is most desirable because it minimizes data loss in the case of a lost, stolen, or damaged device . In addition, this option will not require each 
tablet computer to be in contact [CONTACT_4490] a Wi -Fi hub. As a second option for 
uploading, each census supervisor will have access to  a Wi- Fi hub, and the 
MORDOR Study  
Manual of Operations and Procedures   [CONTACT_73126]  
18 | Page 
 supervisor can visit the census teams to u pload data  regularly . This option is less 
desirable, because the data will be uploaded less frequently. As a third option, 
the data can be uploaded at a central study site, either via Wi- Fi or micro USB 
cable directly in to a computer. This option is least  desirable because is not 
feasible to take the tablet computers to the central site regularly  given the large 
geographical areas of the study.  
 
Census Supervisio n  
The site study coordinator will supervise all census activities. Formal checks of 
census quality will be conducted through the random census  verification . In 
addition, the study coordinator will visualize all censused households using 
imagery from GoogleMaps. The goal of this activity will be to minimize the 
chances of missing large neighborhoods or specific regions within study 
communities. The study coordinator will also check the data entry progress for 
each community, paying special attention at the follow -up censuses , as to 
whether there are any missing data  for the “vital status” variable (i.e., present , 
dead, absent). Once the study coordinator is confident that the entire community has been reached, and that the amount of missing data are acceptable (defined as <10% of children in a community), the study coordinator (or other research team member) will certify the census data collection for that community complete via 
Salesforce . Changes can be made to the record at different time points, but these 
changes will not be reflected until the subsequent census . All changes are time 
and date stamped in the database .  
 
Census Timing  
The census will be performed prior to each mass azi thromycin/placebo 
distribution . Study sites may choose to perform the census activities over a 
discrete time period (e.g., all communities completed over a [ADDRESS_955692] simultaneously in many communities at 
once) or alternatively in a “rolling” fashion (e.g., all communities completed over 
a 6-month period, requiring fewer census teams to be a ctive at once). In either 
case, each community must be censused every [ADDRESS_955693] be completed (i.e., 
“locked”) at the household level before treatment can be given.   
 
6.2. Random  Census Verification  
A random re -census of households will be conducted  at each study visit  by 
[CONTACT_32338], additional census team members, or local community monitors, as 
appropriate for the study site . Verification will be performed at the household  
level, with a minimum of 200 households be ing resurveyed during the 5 study 
visits per country (approximately 40 per visit).  Each team must have at least one household census verified at each study visit.   
MORDOR Study  
Manual of Operations and Procedures   [CONTACT_73126]  
19 | Page 
  
Households will be selected using a different mecha nism than the mechanism 
used by [CONTACT_73071].  The primary method for selecting random 
households will be f rom aerial visualization (Google maps, AfriPop, etc.) If aerial 
visualization is not possible in an area, then another method for obtaining households can be used, such as a random walk.  
 Both census teams will use the same electronic template (i.e., no prior records at MORDOR  0, and the census records from the prior census at each follow- up 
visit) . We will arbitrarily select a sample of communit ies stratified by [CONTACT_703832]. Once the census has been completed, the trial biostatistician will analyze 
the communities  for verification .   
 The trial biostatistician will compare the results of the original census and the re -
census to identify any discrepancies. The steering  committee will determine any 
corrective actions once this comparison is made. At the very minimum, the site study coordinator will inform the original census team of the discrepancies and 
will conduct a refresher training session to minimize data collection errors.  
 
6.3. Verbal Autopsy  
Verbal autopsy  questionnaires will be completed for all deceased children  (aged 
1-60 months) .   
 Staff  
Verbal autops y interviews  will be conducted  by [CONTACT_32341] . Training will focus 
on conducting sensiti ve interviews with persons who may still be in mourning; 
discussion of verbal autopsy questions ; reviewing  the format of the paper 
and/or electronic questionnaires (including skip logic) ; and demonstration of the 
verbal autopsy technique on [ADDRESS_955694] with the k ey 
informant from each community.  
 
Identification of Deaths 
Deaths will be identified in 2 ways: from the biannual  census, and from the key 
informant system. The trial biostatistician will provide a list of all deaths to the 
site study coordinator after e ach census. This list will include information on the 
deceased child’s name, age, gender, and unique identification number; community name; and father’s and mother’s names. Th e study coordinator will 
in turn deliver this list to the appropriate verbal auto psy interviewer . The verba l 
autopsy interviewer will also keep a record of all deaths identified by [CONTACT_703833]. Tom Lietman  
20 | Page 
 informants . In each case, the key informant will report the community name, 
child’s name, and parents’ names, and the deceased child will be located in the 
census database . 
 
Questionnaire Administration  
Each site will choose between the full -length WHO questionnaire ( 2007 version)  
or an abbreviated form (which utilizes questions from both WHO 2007 and 2012), 
translated into the local language  as appro priate . Questionnaires will be 
administered at  the home  of the deceased child. The informant will be the 
deceased child’s parent or guardian. If this person is not available, the verbal autopsy interviewer will try to arrange a time to return to interview this person. If the parent or guardian is not present on the third visit, they will complete the 
questionnaire by [CONTACT_73074], or as a last resort, a 
neighbor. All interviews will be completed i n the local language . Our goal is to 
perform each verbal autopsy within 2 months of identification of death.   The 
child’s name [CONTACT_703852].  
 
Assigning the Cause of D eath 
As recommended by [CONTACT_14300], we will use automated methods to assign causes 
of death  based on the verbal autopsy questionnaire , rather than physician 
review.  We will treat all individuals under [ADDRESS_955695]. Tom Lietman  
21 | Page 
 centers to develop a strategy for obtaining more accurate death registers during 
the study.  
 
CSIs and villages maintain local death registries. Health professionals record deaths that occur in the CSI. The CSI death registries include: name, age, village, cause of death. The village chief also maintains a death registry in the village. 
The village death registry includes: name, age, village, cause of death. 
 The Study Coordinator will visit each CSI and take photos of local death registries with  all deaths from children aged [ADDRESS_955696] that 
both the census and the registry will miss deaths.  
 Verbal autopsies will be performed on all deaths pi[INVESTIGATOR_703815] 0 -5 year- olds pi[INVESTIGATOR_73040]. Note that the 
deaths from the death registry will not be used in the primary outcome.   
6.4.2 Malawi 
Deaths will be identified in 2 ways: from the biannual census, and from the key 
informant system. T he trial biostatistician will provide a list of all deaths to the 
site study coordinator after each census. This list will include information on the 
deceased child’s name, age, gender, and unique identification number; the 
community name; and the father’s  and mother’s names. The study coordinator 
will in turn deliver this list to the appropriate verbal autopsy interviewer. The verbal autopsy interviewer will also keep a record of all deaths identified by [CONTACT_703834]. In each case, the key informant will report the community name, 
child’s name, and parents’ names, and the child will be located in the census database. We will provide phone credit as appropriate for the key informants.  
 
Trained verbal autopsy interviewers will be responsible for a distinct geographic 
area, and will be responsible for being in regular contact [CONTACT_73075]. We will aim to perform all verbal autopsies within 2 months of death. The interviewee will be the deceased child’s parent or 
guardian. If this person is not available, the verbal autopsy interviewer will try to 
arrange a time to return to the home to interview this person. If the parent or guardian is not present on the third visit, they will complete the questionnaire by 
[CONTACT_703835]. Tom Lietman  
22 | Page 
 Protection of Examiner and Study Participant  
Prior to examinations at the blood station and the swab station, the 
examiner and tuber must be gloved. The examiner wi ll put latex gloves on 
both of his/her  hands prior to touching the participant and a new pair of 
gloves wil l be used for each participan t in order to avoid transmitting 
infection between participants . Purell® Instant Hand Sanitizer will be 
available for hand sanitization when needed .   interviewing anothe r family member, or as a last resort, a neighbor. All 
interviews will be completed in Chichewa, Yao or English, as appropriate, on a 
tablet computer.  
 
6.4.3 Tanzania 
Community Monitors will visit a random sample of households identified on the 
census as ha ving children. They will visit their assigned households each month 
to monitor for death s. These records will be kept apart from the  data collected by 
[CONTACT_73076] (at six month intervals). The two lists will be compared and any 
discrepancies followed up.     
 
Chapter 7 : Registering Participants for Specimen Collection 
Samples will be collected with reference to age, gender, household, and 
community, but participant names will not be included in laboratory records  to 
ensure privacy .  Samples will thus n ot be associated with an individual’s name, 
but with a random identification number  and/ or QR code, masking laboratory 
personnel and preventing identification of individuals.   
 At each time point, e ach child selected for examination/specimen collection wi ll 
be assigned an identification number  for database anonymity.  
 
For each community, the randomized registration list for examinations will be 
generated by [CONTACT_73077].   
After registration, the child and his/her guardian  will be  direct ed to  the 
appropriate  examination stations.  
 
Chapter 8: Blood samples  
We will collect:  
1) Thick and thin smears, assessed for malaria parasitemia  and 
gametocytemia  by [CONTACT_703836] , 
MORDOR Study  
Manual of Operations and Procedures   [CONTACT_73126]  
23 | Page 
 2) Microcuvettes, an alyzed for hemoglobin in the field using a Hemo Cue 
analyzer (HemoC ue AB, Ängelholm, Sweden) , and 
3) Dried blood spots, collected on FTA Elute cards (Whatman, Kent, [LOCATION_006]; or 
appropriate substitution ) and sent for laboratory testing for malaria using 
a nested PCR  assa y40 and /or TropBio cards ( Tropbio Pty Ltd, QLD, 
Australia ) and sent to  the CDC for serological testing.  
 
The order of events at the blood collection station is: 1) finger prick; 2) blood spots on filter paper; 3) hemoglobin test; 4)  thin and  thick smear s for malaria.  
 
 
 
8.1. Fingerstick  
Inform the mother that her child’s finger will be pricked to obtain blood to test 
for malaria and anemia. Describe the finger prick procedure , reassure her , and 
answer all questions. The blood specimen should be collected as described below 
to minimize the discomfort of the child and to ensure sufficient blood volume 
collection . 
 
A finger stick of capi[INVESTIGATOR_703816] d for thin and thick blood smear s 
to assess for malaria, hemoglobin testing, and dried blood spots to be stored for 
later testing. Blood will be collected by a gloved health worker using aseptic 
technique. Gloves will be changed between each participant . The fingerprick or 
heelstick site will be disinfected using a  70% isopropyl alcohol swab.  
 
Finger stick procedure : 
1. Prepare the disposable lancet. U se a NEW disposable lancet for each child. 
Do not re -use lancets!  
2. The recorder will scan the child’s QR code , and place  a random number 
sticker on  the TropBio filter paper  and the ( right edge of the ) slide.  It is important to handle all blood specimens with care  
to minimize risk of infection  
 
Wear gloves.  N ew gloves must be worn for each child.  
Clean spi[INVESTIGATOR_3353].  In the event of a blood spi[INVESTIGATOR_73042], clean immediately with 
approved disinfectant (10% bleach or chlorhexidine solution) and wipe with 
absorbent material.  
Disposal of sharps. All lancets must be disposed of properly in sharps 
container s.  
No food.  Food and drink are not allowed at the blood collection station.  
MORDOR Study  
Manual of Operations and Procedures   [CONTACT_73126]  
24 | Page 
 3. Position the child for the finger stick. Make sure that the child’s right hand 
is warm and relaxed. Hold the child’s thumb, middle, or ring finger on 
his/her right hand (from the top of the knuckle to the tip of the finger) 
between your left thumb and finger and disinfect in small outward circles with an individually packaged alcohol wipe.  
4. After the alcohol dries, use the thumb to lightly press the child’s thum b or 
finger from the top of the knuckle towards the finger tip to stimulate blood 
flow towards the  sampling point (puncture site) . For the best blood flow 
and least pain, prick the side of the thumb /fingertip, not the center. While 
applying light pressure t owards the thumb /fingertip, hold the lancing 
device in your hand and prick the thumb /finger. If the finger prick is 
performed properly, a single prick should be sufficient to collect the 
required amount of blood.  
5. Allow the blood to ooze out. Wipe away the first 2 or 3 drops of blood 
with gauze. If necessary, re- apply light to moderate pressure towards the 
thumb/ fingertip (approximately 1 cm behind the site of the finger prick) 
until another drop of blood appears.  
Note: Do not squeeze forcefully . Avoid “milking” as it may dilute the 
blood with tissue plasma.  
 
8.2. Dried B lood  Spot s for M alaria  
 
Collecting the FTA Elute filter paper sample: 
1. Label the filter paper with a random number sticker.  
2. Place 2-[ADDRESS_955697] on the filter paper  (if it is difficult to obtain [ADDRESS_955698] 2 drops of blood) .  
3. Leave the filter paper to air dry for a few minutes, then place the sample 
into a small plastic bag along with a desiccant  packet.   
4. Leave the bag open for a few minutes more,  and when the blood is completely  dry, roll down the top of the bag and close with a pi[INVESTIGATOR_703817].  
5. Store the filter paper samples (in small plastic bag s) in a larger Ziploc bag. 
Keep all filter paper samples in a safe, dry place at room temperature.  
6. Blood spots will be stored at room temperature in a locked cabinet in the study coordinators’ office.   
 
MORDOR Study  
Manual of Operations and Procedures   [CONTACT_73126]  
25 | Page 
 
Collecting the Tro pBio filter paper sample:  
1. Label the filter paper with  a random number sticker.   
2. Grip the filter paper on the side without small circles. Place a droplet 
of blood directly from the thumb or finger onto five  of the six circles, 
leaving the right one blank . Be sure to fill each circle completely.   
    
 
  
 
   
 
3. The recorder will scan  the QR code.  
4. Carefully slide the filter paper onto a pencil to air dry for at least an 
hour. There should be about [ADDRESS_955699] each sample into a small zip plastic 
bag (individually). Place the small bags into a larger Ziploc bag with 
five desiccant packets.   
6. Ensure the large Ziploc bag is sealed tightly, as moisture will damage 
the samples. Transport these filter pape r samples to a freezer.  Area to hold the filter paper.  
Do not touch the small circles . Leave last circle  blank  
MORDOR Study  
Manual of Operations and Procedures   [CONTACT_73126]  
26 | Page 
 Set up HemoCue Analyzer  
1) Remove the HemoCue analyzer  from the case.  If a small battery 
symbol appears on the top right side of the display, the batteries are 
low. The HemoCue will still give accurate results, but it is strongly recommended to replace the batteries as soon as possible.  
2) Pull the cuvette holde r out to the loading position. Press and hold the 
left button until the display is activated (ALL symbols appear on display). The display will show the version number of the program, an hour -glass symbol and “Hb.” At this time, it will perform an 
automatic  SELFTEST to verify the performance of the device. After [ADDRESS_955700] fails, an error code 
will be displayed.  
 
  
Set-up drying area for TropBio bloodspots  
Supplies: pencils, Styrofoam, cardboard box , paper  
- Place Styrofoam in cardboard box  
- Put pencils inbox /container  – space apart 
- Note: When placing the blood spot samples on 
the pencil , space apart by ~2.5cm with pi[INVESTIGATOR_703818].  
 
 
 
 
 
8.3. Hemoglobin  Test  
A portable spectrophotometer (HemoC ue, Anglom, Sweden) will be used for 
hemoglobin testing.  
Collecting a blood sample for he moglobin (HemoCue): 
1. Remove a cuvette from the container. Reseal the container immediately.  
(The recorder can help the examiner with this.)  
2. When the blood drop is large enough, fill the microcuvette in one 
continuous process. Do not refill! If there is not enough blood to fill the 
microcuvette, you must start again with a new microcuvette. Wipe any excess blood from the sides of the microcuvette with clean gauze or a paper towel, but be careful to avoid touch ing the open end of the 
microcuvette  so blood is not removed . 
3. Look for any air bubbles in  the filled microcuvette. If air bubbles are 
present, discard the microcuvette and obtain a new drop of blood using a 

MORDOR Study  
Manual of Operations and Procedures   [CONTACT_73126]  
27 | Page 
 Clean ing the HemoCue Analyzer  
1) To clean, pull the cuvette holder to the loading position.   
2) Carefully press the small catch (upper right corner of the cuvette 
holder). Continue to press the catch and carefully rotate the cuvette holder as far left as possible, and then carefully pull the cuvette holder 
out of the analyzer.   
3) Clean the cuvette holder with alcohol or a mild detergent. Push a clean 
cotton tipped swab moistened with alcohol (without additive) into the opening of the cuvette holder and move from side to side 5 – 10 times. 
If the swab is dirty, repeat with a new clean swab until the cuvette 
holder is clean. A dirty cuvette holder may cause the HemoCue analyzer to display an error code.  
4) After 15 minutes (or less time, depending on the climate), you may 
replace the cuvette holder and use the analyzer. The cuvette holder 
must be completely dry before you replace it.  
5) Put the Hemocue analyzer back into its case.  
 
 
 new microcuvette.  (Small bubbles around the edge of the microcuvette can be ignored.)  
4. Place the filled microcuvette in the cuvette holder . Gently slide the cuvette 
holder to the measuring position to be analyzed immediately. (This must 
be performed within 10 minutes  after filling the microcuvette. ) 
5. After 15 – 60 seconds, the hemoglobi n value will be displayed. The 
examiner should read the h emoglobin value aloud so the r ecorder can  
enter it into the tablet computer. The value will remain on display as long as the cuvette holder is in the measuring position. The analyzer will turn off automatically after 5 minutes.   
Note:  For children 6 months to 5 years, if the hemoglobin is <11.0 g/dL, 
the child is anemic. For children 5 – 11 years, if the hemoglobin is <11.5 g/dL, the child is anemic (WHO/UNICEF/UNU, 1997). If  a child is found 
to be severely anemic, the e xaminer must refer him/her to the ne arest 
health center for treatment.  
6. Carefully dispose of the used microcuvette in the sharps container.    
7. At the end of the day: Turn off the HemoCue analyzer. Press and hold the 
left button until the display reads OFF. The display should be blank.  
8.4. Thick and Thin Smears for M alaria  
1. Label the slide with a random number sticker.  
2. For the thick blood smear:  
a. Place a drop of blood in the center (1 cm from the edge of the slide) 
of a clean, dust-free, and grease- free slide.   
MORDOR Study  
Manual of Operations and Procedures   [CONTACT_73126]  
28 | Page 
 b. Spread the drop of blood evenly with a disposable wooden 
applicator or with another clean slide into a circle with a diameter 
of [ADDRESS_955701] thickness of a thick blood smear is one through which newsprint is barely visible when the blood is still wet.  
3. For the thin blood smear:  
a. Place a smaller drop of blood on the slide.  
b. Using another slide angled at 45°, create a feathered edge before reaching the other end of the slide.  
4. Allow the blood smears to air dry flat. Do not heat the slides, as this will damage the parasites. Be sure to protect the slide from dust and insects. Do not refrigerate slides, as this may cause the smears to detach from the slide during the staining procedure.  
5. When dry, place the thick and thin bl ood smears into the slide box.  
6. Smears will be transported at room temperature each day to a diagnostic facility near the study area.  
7. Within 24 hours of thick and thin blood smear collection, the smears will be stained with 2% Giemsa stain for 30 minutes. (The thin smear will be fixed by [CONTACT_73079] 100% methanol for 30 seconds and then let it air dry for 1 -2 minutes prior to the Giemsa stain.)  
8. Parasite density will be measured by a masked reader using a microscope at the diagnostic facility.  
 Smears  will be stored at room temperature . 
 
A rapid diagnostic test (RDT) could be substituted for thick smears if approved 
by [CONTACT_40972].  
 
 
8.5. Materials for Blood Collection  
 
Fingerprick  
Gloves  Disposable lancets  
Alcohol wipes  
Cotton balls  
Gauze  
10% household bleach or 4% chlorhexidine solution to clean spi[INVESTIGATOR_703819]. Tom Lietman  
29 | Page 
 Dried Blood Spot s 
FTA Elute cards  
Small zip plastic bags  
Desiccant packs  
Masking tape  
Large Ziploc bags (handful)  
TropBio circular cards  
Small zip plastic bags  
Desiccant packs  
Large Ziploc bags (handful)  
Materials for drying apparatus: [ADDRESS_955702]  
HemoCue machine  
Extra set of AA batteries  
Cuvettes  
Q-tips (handful)  
 
Thick  and Thin Blo od Smear s 
Glass slides  Slide box  
 Rolls of r andom number stickers  
 
Google Nexus 7  
External battery pack  
Chapter 9: Specimen Collection for Resistance Testing   
 
9.1.  Population  
We will collect nasopharyngeal  and stool samples on a random set of [ADDRESS_955703]. Tom Lietman  
30 | Page 
 9.2 Nasopharyngeal Swabs  
Nasopharyngeal swabs will be stored in DNA/RNA shield media by [CONTACT_703837], and standard microbiologic techniques will be used to isolate S. 
pneumoniae  and test for resistance to azithromycin, penicillin, and clindamycin. 
Resistant isolates will be assessed for the most common genetic resistant 
determinants ( ermB  and mef A) using a PCR -based assay.[ADDRESS_955704] common serotypes, followed 
by [CONTACT_73081].42 
 
The examiner will:  
1. Place a pediatric f locked s wab  with a nylon tip  through the right 
nostril and  down the nasopharynx of each participant . Note that if the 
swab is not perpendicular to the frontal plane of the face, it is likely not 
in the inferior turbinate.  
2. Once you reach the nasopharynx, r otate the swab 180° as you  remove 
the swab from the nose.  
3. Place the swab in a tube containing 1.0 mL D NA/RNA shield media 
by [CONTACT_73082] (skim milk, tryptone, glucose, and glycerin) media, cut the handle off using sterile scissors, and close the cap of the tube with the swab immersed.  
4. The nasopharyngeal swab samples in STGG will initially be stored in the field at 4°C using an insulated storage bag with Fisher brand ice gel 
packs, and then transferred to -20°C. The nasopharyngeal swab samples in DNA/RNA shield media will be stored in ambient 
temperature in the field. Then transferred to a refrigerator or f reezer.  
5. The scissors used to cut calcium  alginate swabs will be sterilized with 
alcohol pads  or cleaned with bleach wipes  between participants.  When 
collecting specimens in DNA/RNA shield, scissors will be cleaned 
between participants - first with bleach wipes, and then with alcohol 
pads.  
 
Do not attempt to collect the  NP swab if you are not successful after  three  attempts.  
9.2.1 Materials for Swab Collection for Resistance Testing  
 
Swabs  
NP specimens will be collected using sterile, individually -wrapped pediatr ic 
flocked  swabs with a plastic  swab shaft (m anufactured by [CONTACT_73083] ). Nasal sites 
will be swabbed with  a sterile,  Dacron polyester -tipped swab with a plastic shaft 
(manufactured by [CONTACT_73084]).   
 
Sample Tubes  
MORDOR Study  
Manual of Operations and Procedures   [CONTACT_73126]  
31 | Page 
 All field samples for DNA testing will be collected into sterile 2.0ml 
microcentrifuge tubes, manufactured by [CONTACT_73085] ®. (DNA -free tubes will be used 
for collection in DNA/RNA shield.)   
 
Cooler Bags with Frozen Ice Packs 
Insulated cooler bags  will be used to carry samples to and from the field.  In 
addition, frozen gel ice packs designed to thaw slowly will be used to maintain 
the temperature in the cooler bags during transport.  
 
-20°C Freezer 
A standard -20°C freezer located at the local health center will be used strictly for 
the storage and free zing of ice packs and samples. This freezer is kept in a locked 
room on the grounds of the Health Center, which is under [ADDRESS_955705] be carefully followed  in order to prevent 
contamination and ensure the safe transport of the samples back to the local 
microbiology laboratory and/ or to the US for processing .  The person in charge 
of labeling, tubing, arranging, and handling the samples needs to perform this 
task in the most orderly and attentive manner.  
 
1. Both hands of the tuber should be gloved at all times. The tuber's gloves 
only need to be changed when any potential contamination of the gloves 
occurs. The tuber opens the capped, hinged lid of a microcentrifuge tube, 
which has been labeled with the participant’s random identification number.  
2. The swab is inserted by [CONTACT_703838].  The swab shaft should only be inserted until the swab head 
is fully in the tube. T he tuber will cut the swab shaft with sterile scissors.   
3. The tuber should screw the cap of the microcentrifuge tube tightly, flick the tube to mix the sample with the media (for tubes with DNA/RNA 
shield media),  and place it in the sample collection box, located in the 
cooler bag filled with frozen ice packs. The flap of the cooler bag should 
be closed between each patient.  The cooler bag should be in as cool a 
place as possible in the field, in a shaded area out of the sun.  
Upon returning from the field e ach day, the samples in STGG will be 
immediately taken to a local h ealth c enter and stored in a commercial -20°C 
freezer, reserved solely for storage of specimens and ice packs.  All samples will be in sample boxes, labeled with the village name  [CONTACT_703853] f uture identification.  
MORDOR Study  
Manual of Operations and Procedures   [CONTACT_73126]  
32 | Page 
 9.[ADDRESS_955706] of either culturing/microbiological testing or nucleic  acid based testing.   
 
Rectal Swabs  for Culturing/Microbiological T esting  
Rectal swabs will be collected and placed into Amies transport media  or Norgen 
Stool Preservative . We will use standard microbiologic techniques to isolate 
Escherichia  coli. Resist ance to azithromycin, ampi[INVESTIGATOR_10312], and co -trimoxazole will be 
determined. Isolates can be further classified into commensal and diarrheagenic 
subtypes using a multiplex PCR assay.43  
 
Stool Samples for Nucleic Acid Based Testing  
Stool specimens will be used to look for the presence of E. coli  and macrolide 
resistant determinants typi[INVESTIGATOR_73046] E. coli, u sing 
a resistome approach. This will be carried out by [CONTACT_703839] E. coli as well as genes associated with antibiotic resistance (i.e. erm , mef , and mph genes)  via PCR assays.
[ADDRESS_955707] the presence of 
toxins or virulen ce factors (i.e. eae, stx, bfp- A,VT -1, VT-2) , which are linked to 
diarrheagenic E. coli strains,46-47 or exploring the  complete  microbiome of the 
stool specimens.  
 
9.3.1 Stool Specim en C ollection  
 
Rectal Swab  Collection for Culturing/Microbiological T esting  
The test will require that the child’s parent and examiners  work together to 
obtain a good sample.  Is it important to describe the test to the parent so that 
they can best assist  with keepi[INVESTIGATOR_73047], if 
necessary.  
    
In place of stool specimens, rectal swabs can be collected in the following way:  
1. Put on a clean pair of gloves . 
2. Partially open the fecal swab package and remove the top section of the 
collection vial (this can be discarded).  
3. Position the child:  
• Lie the child on his/her back, hold legs in the air (it is useful to have assistance).  
• Or have the child lay on his/her stomach across the mother/guardian’s lap 
4. Remove the swab from the package . Take care that the cotton tip is not 
touched.  If it is touched, throw the swab away and begin with a new one.  
MORDOR Study  
Manual of Operations and Procedures   [CONTACT_73126]  
33 | Page 
 5. Insert the tip of the swab into the child’s anus only as far as needed to 
contact [CONTACT_73088] (1- 3cm) and rotate [ADDRESS_955708] swab into the preservative in the collection tube. Make sure the swab is fully submerged in the liquid preservative and then break the swab off using the pre -scored breaking point.  
7. Screw the cap back on the tube and make sure that it’s tightened. Wrap the area where the cap meets the tube with Parafilm to ensure that the sample will not leak, and then place the tube into the appropriate sample box.  
• If the swab cannot be broken off while the tip is fully submerged in the liquid, try twirling the swab in the liquid first (to release the 
contents of the sample into the preservative) before breaking it off. 
Avoid rubbing the sample on the tip of the swab off on the side of the tube where there is no liquid.  
8. Place a random  number label on the collection tube.  
9. Place the tube the rectal swab container.  
10. Swab storage for Genetic analysis:  Store samples at room temperature. 
According to the manufacturer, the preservative in the tube will preserve 
DNA for 5 months at room tempera ture (7 days for RNA), and thereafter 
can be frozen (-20°C or -80°C) for long- term storage.  
 
Stool Specimen Collection for Nucleic Acid Based Testing  
For the study participant/parent of the child:  
1. Collect  the initial stool specimen on a pi[INVESTIGATOR_73048].   
2. Transfer a few heapi[INVESTIGATOR_73049], 4 oz 
disposable plastic container that has a locking lid, using the spoon 
provided. Return this to the trained field worker.  
 
For the trained field worker:  
1. Wearing fresh gloves, c areful ly place a portion of the stool sample  from 
the disposable 4 oz plastic container into a labeled Norgen Stool Nucleic 
Acid Collection and Transport Tube (15 ml collection tube that contains 
preservative), using the small spatula tha t is attached to the tub e’s cap. F ill 
up to the line as indicated by [CONTACT_73089] .
[ADDRESS_955709]. Tom Lietman  
34 | Page 
 5. Place the tube into the storage box and store at room temperature.  
6. Once the final stool sample has been collected in the Norgen Stool Nucleic 
Acid  Collection and Transport Tube, wrap up the initial stool sample in 
the large receptacle container using the plastic lining and properly dispose 
of it. Also, dispose of the stool sample in the 4 oz plastic container and the spoon that was used.  
 
9.3.2 Materials for Stool Specimen Collection  
 
Rectal Swab Collection for Culturing/Microbiological T esting  
Swab  
An i ndividually -wrapped Copan flocked  swab with a plastic  shaft  will be used 
to collect the rectal swab and then placed into a Stool Nucleic Acid Collection 
and Transport Tube  contain ing Norgen Stool Preservative  or Amies Transport 
Medium .   
 
Sampl e Tube  with Media  
The specimen will be in a sterile Stool Nucleic Acid Collection and Transport 
Tube containing Norgen Stool Preservative  or Amies Transport Medium wi th a 
cap that will be tightened firmly.  
 
Stool Specimen Collection for Nucleic Acid Based Testing  
Plastic Lining  
Each participant will be given a pi[INVESTIGATOR_703820].  
 
Spoon 
Wooden medical spoon used to transfer a portion of the initial stool specimen to 
the small plastic container, which will be brought to the trained field worker by [CONTACT_7071].  
 
Small Plastic Container  
4 oz disposable plastic container with locking lid used to transport a  portion of 
the initial stool specimen to the trained field worker.  
 
 
9.4 Quality Control Measures for Specimen Collection  
 Negative Field Controls  
Negative field control swabs for NP and stool will be taken in each community to 
assess for contamination: one c ontrol swab  each (NP and stool /rectal ) are taken 
MORDOR Study  
Manual of Operations and Procedures   [CONTACT_73126]  
35 | Page 
 before specimen collection begins in a community; and another (NP and 
stool /rectal ) upon completion of specimen collection.  
1. For each negative field control, the examiner will open a new swab as described ab ove.  
2. Wave the swab in the air, without making contact [CONTACT_73090]/anything.  
3. Tube the swab in media, as described above.  
 
Duplicate swabs  
Duplicate NP swabs and rectal swabs/stool specimen will be collected from two 
children per community.  
 
 
Chapter 10: Cost -Effectiveness   
 
10.1. Costs 
We will record the costs of distributions in a random subset of 12 villages at 
MORDOR 6 or 12 and MORDOR 24. We will assume a societal perspective. 
Programmatic costs  will be included, such as: azithromycin, antibiotic 
distributo rs, supervisors, drivers, fuel, and the time of community volunteers , 
and the costs of azithromycin will be estimated using the market price for generic formulations.  See appendix for the study forms to be used. Collection of 
certain costs will be incorpor ated into the electronic data capture system, 
including the duration of time that the antibiotic distributors worked, the 
number of antibiotic distributors per team, the number of doses of 
azithromycin /placebo  given, and the number of doses of azithromycin /placebo  
wasted. Other costs will be collected on paper forms from the appropriate 
parties: the drivers will complete paper forms describing costs of fuel and automobile maintenance, and the study coordinator will complete paper forms 
describing the costs of consumables purchased for the study, as well as the 
overhead costs of maintaining the mass drug administration office.  
 
10.[ADDRESS_955710] their person -
time counted in the mortality outcome, regardless of whether they are 
enumerated at the previous census. Similarly, we will count all childhood deaths 
in the study area, even if the child never appears on the census. The effectiveness outcome  will therefore include children who are born and die within an inter -
censu s interval. Estimating the effectiveness will require several aspects from the 
census data collection:  
MORDOR Study  
Manual of Operations and Procedures   [CONTACT_73126]  
36 | Page 
 • Pregnancies. At each census, we will ask whether any household 
members are pregnant, and at the follow- up census , inquire about the 
status of the fetus, recording the date of births and deaths.  
• Dates of Births, Deaths, and Migrations. These dates will be obtained in [ADDRESS_955711] dates of all births, deaths, and migrations among ch ildren aged 1- 60 months, and will report these data to the verbal 
autopsy interviewer . The verbal autopsy interviewer  will enter these data 
into a separate section of the electronic data capture system . 
Chapter 11: Training   
 
11.1 Standardization  
The three coll aborating institutions – UCSF, JHU, and LSHTM – will work together 
prior to MORDOR 0 to standardize all study procedures . We will review the format, 
general logistics , and procedures for the house -to-house census. The i mportance of 
capturing the vital status of every individual in the study area, including individuals 
not on the previous census (i.e., new births , deaths  and migrations)  will be stressed. 
The importance of capturing those individuals who were born and died in the time 
period between two  censuses will also be highlighted. Census workers who have 
successfully completed the training will be certified, although certification can be 
revoked on subsequent quality control checks . Ongoing t raining activities ( before 
each biannual census ) should consist of didactic classroom instruction and mock 
census activities, followed by [INVESTIGATOR_2993] -field training , review ing the use of the electronic 
data capture, including charging devices and troubleshooting technical problems.  
11.2 Pi[INVESTIGATOR_703821] 0 , non -study  communities at each study site will be randomly 
selected as “pi[INVESTIGATOR_2268]” villages from the same pool as the mortality and morbidity communities. The research team will conduct all of the study procedures as 
described in the mortality study and morbidity study (c ensus, sample collection, 
and treatment) in these pi[INVESTIGATOR_73052]. Similar to the 
morbidity and resistance communities, samples will be collected from 40 
children, aged 1 – 60 months  and 40 children, aged 7 – 12 years . For morbidity, 
blood samples (thick smears, microcuvettes, dried blood spots), conjunctival 
MORDOR Study  
Manual of Operations and Procedures   [CONTACT_73126]  
37 | Page 
 swabs, and anthropometric measurements (height, weight, MUAC) will be 
collected. For resistance, nasopharyngeal, nares swabs, and stool specimens will 
be collected. Consent will be  obtained from the village chiefs and the parents/ 
guardians of each child prior to sample collection. Everyone in pi[INVESTIGATOR_703822]. If the results of the trial are positive, everyone in these villages will also be treated with mass 
oral azithromycin at the end of the study.  
 
 
Chapter 12: Sample Organization, Transport,  and Storage 
 
12.[ADDRESS_955712] access to the key linking the ID with census 
information.  Age, gender, and community of residence will be available for each 
specimen, but names will be kept confidential.  Therefore, all specimens will be 
de-identified.  
 
12.2 Specimen Transport  
After sample collection, samples from the field will be transported to a local 
health facility or research center at each study site.  
 During any international specimen transport, the temperature of the shipper 
boxes will be documented by a temperature recording device . 
 
Blood Samples  
Blood smears  (thin and thick)  will be transported at room temperature to a local 
laboratory (depending on capacity at each study site).  FTA Elute cards will be 
transported at room temperature and stored at the health clinic before being 
transported for processing. TropBio cards will be transferred on ice to the health center and stored at - 20°C prior to shipment.   
 
Swabs  
Swabs in STGG  media will be initially stored in the field at -4°C using a closed, 
insulated container until arrival at a securely locked freezer at -20°C. Swabs in 
DNA/RNA Shield media will be stored in ambient temperature in the field and 
then transferred to a refrigerator or fr eezer.  
 Clinic -based Swabs (non- core ) 
NP swabs in STGG media  will be stored in the - 20°C freezer at the hea lth 
clinic, and then transported for processing . NP swabs in DNA/RNA 
MORDOR Study  
Manual of Operations and Procedures   [CONTACT_73126]  
38 | Page 
 Shield media will be stored in ambient temperature at the health clinic, 
then t ransported for processing.  
 
Stool Samples  
Rectal Swabs for Culturing/Microbiological T esting  
Rectal swabs preserved in Amies  transport medium  should be refrigerated until 
processed. If specimens will be kept more than 2 to 3  days before being cultured, 
it is preferable to freeze them immediately at -70°C. It may be possible to recover 
pathogens from refrigerated specimens up to 7 days  after collection; however, 
the yield decreases after the first 1 or 2 days. Frozen specimens should be 
transported on dry i ce. 
 
Stool Samples for Nucleic Acid Based Testing   
Specimens preserved in Norgen Stool Nucleic Acid Collection and Transport 
Tubes can be left at room temperature for 7 days (if preserving RNA) or up to 5 months (if preserving DNA). Specimens can also be t ransported in the 
preservative at room temperature. If the samples will be kept for long term storage, they can be placed in a -20°C or -80°C freezer.  
 
12.3 Specimen Storage  
Sample storage will occur in two stages:  short -term and long -term  
 
12.3.1 Short -term Sample S torage  
Samples  will be labeled with study ID only and are unidentifiable without access 
to the study database. Lab capacity and sample export regulations vary between 
study sites. If there is capacity to perform sample processing in a quality manner 
(as d ictated by [CONTACT_73091]), samples will be processed in -
country. Otherwise, samples will be shipped to UCSF, JHU, or LSHTM to 
process core samples and any secondary processing.  
 
12.3.2 Long -term Sample S torage  
Depending on each study site’s sample export regulations, allowable de -
identified samples from Malawi, Niger,  and Tanzania will be shipped to UCSF 
for longer -term storage at the UCSF Oyster Point Facility, which is designed 
particularly for secure long -term (5 years) storage of biological speci mens , at -
80°C for future analyses by [CONTACT_73092].    
 
12.[ADDRESS_955713]. Tom Lietman  
39 | Page 
 while banked at UCSF.  This will facilitate identification of specimens for future 
analyses.  
 
Chapter 13: Microbiology and Molecular Laboratory Procedures  
Participant names will not be included in laboratory records  and samples will be 
de-identified.  Therefore, l aboratory personnel will be masked, prevent ing 
identification of the individuals infected.  Lab results will not be available for 
weeks , if not months.  Thus , all individuals will be treated according to their 
study arm, whether or not their lab tests reveal evidence of infection.  
 
13.1 Storage  and Transport  Media 
 13.1.1 Preparation of STGG Transport  Medium  
Intended Use  
STGG was originally used for long term storage of bacteria at - 70C. This media 
has also been used to successfully transport and recover bacteria from specimens 
collected on swabs.   
 
Formula  
 
Procedure  
 
1. Combine fo ur ingredients in flask and swirl to dissolve (about ½ 
hour).  Use glass cylinder to measure Glycerol.  Dispense solution 
in 1.0ml amounts into screw- cap 1.5ml vials (Sarstedt Microtube, 
Newton, N.C.) Use Sarstedt rack for easy dispensing.   Ingredients per number of 1 ml vials  
Ingre dients  1 50  100  200 300 400 500           1000  
Skim milk powder  
(Difco, Detroit, Mich.)  
Cat.232100 500g  .02g 1g 2.0g 4g 6g 8g 10g              20  
Tryptone soy broth  
(Oxoid -CM129 500g) 
Fisher cmo129  .03g 1.5g 3.0g 6g 9g 12g 15g              30g  
Glucos e (Difco -
Dextrose cat 215530, 
500g)   .005g  .25g .5g 1g 1.5g 2g 2.5g               5g  
Glycerol (Difco - cat 
228220 500g)  .1ml  [ADDRESS_955714]. Tom Lietman  
40 | Page 
 2. Autoclave vials with caps screwed on loosely at 1 5 lb/in2 and [ADDRESS_955715] vials in plastic storage boxes (boxes will not close 
when cooled). Use old bottom from broken boxes.  
4. STGG should appear milky white to light tan in color with a precipi[INVESTIGATOR_703823].  
 
Storage and Shelf Life  
Cool vials after autoclaving, screw caps tightly and store at -20 or 4C until use. 
Use vials within 6 months of preparation . 
 
13.1.2 Preparation of Zymo DNA/RNA Shield
TM 
 
Manufacturer’s Product Description 
DNA/RNA ShieldTM ensures nucleic acid stability during sample 
storage/transport at ambient temperatures, preserving the genetic integrity and 
expression profiles of samples. There is no need for refrigeration or specialized 
equipment. DNA/RNA ShieldTM effectively lyses c ells and inactivates nucleases 
and infectious agents (virus), and it is compatible with various collection and 
storage devices (vacuum tubes, swabs, nasal, buccal, fecal, etc.).  
 
Materials Required  
 
Product  Supplier  Catalog No.  
DNA/RNA ShieldTM 
1X solution Zymo Research 
Corp.  R1100 -50 (50 ml)  
R1100- 250 (250 ml)  
2ml Loop Screw Cap Micro Tube, PCR 
Performance Tested  
(DNA -, DNase -, RNase -, & PCR inhibitor -free)  Sarstedt Inc.  72.694.416  
Insert for Loop Screw Cap, Violet  Sarstedt Inc.  65.713.007  
 
Procedure  
1. Prepare tubes by [CONTACT_73093] (these 
are for color coding purposes to help distinguish the DNA/RNA Shield 
solution from other media being used in the field).  
2. Before aliquoting the DNA/RNA Shield, gently mix the solution by [CONTACT_703840] a few times (trying not to create too many bubbles) to ensure that the solution is homogenous. In a clean 
biosafety cabinet, use sterile technique to aliquot [ADDRESS_955716]. Tom Lietman  
41 | Page 
  
Storage and Shelf Life  
Store prepared tubes at room temperature (20°C-25°C) until use ; do not freeze 
solution prior to collecti ng samples . Zymo guarantees the shelf -life of 
DNA/RNA Shield TM up to [ADDRESS_955717] suppliers of culture media.  It is usually used at a concentration of 2 grams in every 100 ml distilled 
water. Fisher Scientific has  a dry powder  that’s available and can be used to 
prepare  the media in house.  
 
Procedure  
1. Prepare as instructed by [CONTACT_3455]. Dispense the well -mixed 
medium into screw -cap tubes. Sterilize by [CONTACT_73095] (with caps 
loosened) at 121°C for [ADDRESS_955718] at room temperature (away from direct light) until use. Refer to the 
manufacturer’s instructions/guidelines for specifics on expi[INVESTIGATOR_1659].  
 
13.1.4 Preparation of Nutrient Agar Medium/Slants  
For isolate storage and shi ppi[INVESTIGATOR_007] , blood agar base (BAB), tryptone soy agar (TSA), 
heart infusion agar (HIA) and nutrient agar are examples of good storage media 
for enteric organisms.  Nutrient agar slants will be used to store/ship isolates 
originating from samples such as the recta l swabs. Nutrient agar medium is best 
prepared from ready to use dehydrated powder, available from most suppliers of culture media (i.e. Fisher Scientific). In general, nutrient agar is used at a concentration of 2.8 g in every 100 ml distilled water.  
 
Procedure  
1. Prepare as instructed by [CONTACT_3455]. Dispense the well -mixed, pre -
melted agar medium into tubes (anywhere from 3 -5 ml, depending on the 
size of the tube). Sterilize by [CONTACT_73096] (with caps loosened) at 
121°C for [ADDRESS_955719]. Tom Lietman  
42 | Page 
 2. While the tubes are still hot after autoclaving, place them in a slanted 
position to provide a short slant and deep butt (2 to 3 cm). Once medium 
is cooled and agar is set, caps can be tightened and slants should be ready 
for use.  
 *To inoculate, use an inoculati ng loop to streak the  isolate onto the surface of the 
agar slant. Incubate overnight at 35° to 37°C.   
Storage and Shelf Life  
Prepared nutrient agar slants can be stored in a cool dark place and may have a 
shelf life of up to [ADDRESS_955720] contamination or deterioration. Refer to the manufacturer’s 
instructions/guidelines for specifics on expi[INVESTIGATOR_1659].  
 
13.[ADDRESS_955721] the disc into a 1.5 ml 
microcentrifuge tube. *When processing multiple samples at a time, make 
sure to follow the cleaning protocol below in between punching samples.  
2. Add [ADDRESS_955722] it in a 
heating block set to 95 °C for [ADDRESS_955723].  
5. Store eluted DNA at - 20°C until ready for use. It is best to run PCR as 
soon as possible after extracting DNA. Use 5 ul of eluted DNA in CytB 
PCR re actions (50 ul reaction) as outlined below.  
 
MORDOR Study  
Manual of Operations and Procedures   [CONTACT_73126]  
43 | Page 
 Punch Cleaning Protocol  
1. In between each sample, swirl the Harris Micro -Punch in a beaker 
containing a 1:10 bleach solution for a few seconds and then swirl the 
tip in a beaker containing a 70% ethanol solution.  Dry/blot the tip on a 
clean paper towel and then allow the punch to air dry for a couple of 
seconds before using. Discard the used paper towel in the biohazard 
waste.  
a. Blank control - After cleaning the punch, you may want to take a blank punch from a clea n FTA Elute card with no sample and 
use it as a negative control to confirm that there is no cross contamination.  
2. Clean the cutting mat with a Mini Hypewipe (bleach wipe) and then 
wipe down with ethanol solution using a paper towel. Discard bleach 
wipe and paper towel in the biohazard waste. (You only have to clean the mat every couple of samples, as long as you use different areas of the mat to punch out each sample – for example, you can clean the mat 
after every 4 samples if the samples are punched out in four different quadrants of the mat).  
 
Amplifying Gene Regions (PCR)  
1. Set up first round of PCR with outer primers:  Protocol was adapted 
from Hsiang, et al. & Steenkeste, et al. papers40,45 and based on 
guidelines provided for Qiagen TopTaq DNA Polymerase (refer to Qiagen TopTaq PCR Handbook).
[ADDRESS_955724]  GAGAATTATGGAGTGGATGGTG  
Inner 
Reverse  TGGTAATTGACATCCAATCC  
 TopTaq PCR Buffer (10X)  5 ul 
dNTPs (10 mM)    [ADDRESS_955725] Primer (10 uM)   2 ul 
Reverse Primer (10 uM)   2 ul 
Template DNA    5 ul 
10x CoralLoad Dye   5 ul 
Taq Polymerase            0.25 ul 
Water                       29.75 ul 
  Total Volume:             [ADDRESS_955726]. Tom Lietman  
44 | Page 
  
Note: When setting up several PCR reactions,  make up a mastermix 
for each primer set by [CONTACT_703841] (making up 2 -3 more reactions than needed). 
Aliquot out 45 ul of mastermix for each reaction and then add 5 ul  
of template DNA for each sample.   
 
• Use the following cycling conditions for the  Bio-Rad S1000 
thermocycler:  
Initial step: 95 °C for 5 min  
*Denature: 94°C for 30 sec 
Anneal: 60°C for 90 sec 
Extend: 72 °C for 90 sec 
Repeat from * (Denaturing step to extensio n step) for 40 cycles  
Final step: 72 °C for 10 min  
 
2. Set up second round of PCR with inner primers:  
a. Use the same recipe as above, but use the specific set of inner 
primers instead of the outer primers for each reaction. Also, use 
5 ul of amplicon DNA (DNA fr om first PCR reaction)  as your 
target.  
b. Use the same cycling conditions as above.  
 
Detecting PCR Products  
Use gel electrophoresis to detect and verify the size of expected PCR products.  
 
If running a single -comb 2% agarose e- gel (12 samples total, including  
MW marker): 
1. Load each well that you plan to add a sample to with [ADDRESS_955727] wells. Load 20 ul of water into any remaining empty 
wells.  
2. Load 15 ul of water into the well des ignated for the MW marker, 
and then add 5 ul of the marker to that well.  
3. The single -comb 2% e- gel needs to run for about 30 min.  
 
If running a double -comb 2% agarose e-gel (16 samples total, plus 2 MW 
markers):  
1. Load each well that you plan to add a sample to with [ADDRESS_955728]. Tom Lietman  
45 | Page 
 2. Load 5 ul of water into the well designated for the MW marker, and 
then add 5 ul of the marker to that well.  
3. The double -comb 2% e- gel needs to run for about 15 min.  
 
If running a 48 2% agarose e-gel (48 samples, plus 4 MW markers):  
1. Load each well that you plan to add a sample to with [ADDRESS_955729] wells. Load 15 ul of water into any remaining empty 
wells.  
2. Load 10 ul of water into the well designated for the MW marker, 
and then add 5 ul of the marker to that well.  
3. The 48 2% e- gel needs to run for about 20 min. on program “EG”. 
 
(For e -gel procedures: see  technical manual for running the gel on the Mother 
E-Base – Do not do a pre -run, but remember to set up the program for the E -
base and to place the gel in the E -Base before loading the samples in the gel)  
 
Purifying PCR Pr oducts of Positive Samples  
Use Qiagen QIAquick PCR Purification kit and corresponding protocol, eluting 
the DNA in [ADDRESS_955730]. Tom Lietman  
46 | Page 
  
Procedure  
 
1. Add 5 volumes of Buffer PB to 1 volume of the PCR sample and mix . In our case 
transfer whatever is left of the PCR sample (about 45 ul) to a clean 1.[ADDRESS_955731] a QIAquick spin column in a provided 2 ml collection tube.  
 
4. To bind DNA, apply the sample to the QIAquick column and c entrifuge for 30 –
[ADDRESS_955732] the QIAquick column back into the same tube.  
 
6. To wash, add 0.75 ml Buffer PE to the QIAquick column and centrifuge for 30 –
[ADDRESS_955733] the QIAquick column back in the same tube. 
Centrifuge the column for an additional 1 min. IMPORTANT : Residual ethanol 
from Buffer PE will not be completely removed unless  the flow -through is 
discarded before this additional centrifugation.  
 
8. Place QIAquick column in a clean 1.5 ml microcentrifuge tub e. 
 
9. To elute DNA, add 50 μl water (pH 7.0–8.5) to the center of the QIAquick 
membrane and centrifuge the column for 1 min. Alternatively, for increased 
DNA concentration, add 30 μl water to the center of the QIAquick membrane, 
let the column stand for 1 min, and then centrifuge. IMPORTANT : Ensure that 
the water is dispensed directly onto the QIAquick  membrane for complete elution 
of bound DNA. The average eluate volume is 48 μl  from 50 μl elution buffer 
volume, and 28 μl from 30 μl elution buffer. Elution efficiency is dependent on 
pH. The maximum elution efficiency is achieved between pH 7.0 and 8.5. When 
using water, make sure that the pH value is within this  range, and store DNA at –
20°C as DNA may degrade in the absence of a buffering  agent.  
 
MORDOR Study  
Manual of Operations and Procedures   [CONTACT_73126]  
47 | Page 
  
Speciation via Sequencing  
Sequetech  will automatically quantify the amount of DNA that we send them, 
and, based on their readings , they will adjust the DNA concentration and 
optimize the sequencing reaction.  For a PCR product that is about 800 bp, they 
only use about 4 ng of DNA for each sequencing reaction.  All the primers that 
they use in their sequencing reactions are at a concentration of 1.6 uM and they 
only need 2 ul per reaction.  
 
Preparing the samples for  Sequetech  
Note: Send primers and t emplate DNA (your samples) in separate tubes – if you 
premix them, then they cannot quantify your DNA accurately and cannot 
optimize the sequencing reaction. Also, make sure that all tubes are labeled 
clearly and match the names that you enter on the order  form.  
 
1. Aliquot [ADDRESS_955734] sequenced into a 1.5 ml microcentrifuge tube and label it clearly 
(this should be enough DNA for them to sequence each sample both 
ways).  
2. Make up each nested  primer (keep t he forward and reverse primer in 
separate tubes) that corresponds to your PCR product at a concentration of 3 uM. To do this take 3 ul of the 100 uM stock solution and add it to 97 ul of TE (this will give you a total volume of 100 ul). Based on the number  of sequencing reactions you are ordering, 
calculate how much of the 3 uM primer solution you need to aliquot and send.  
*They will need approximately 1.07 ul of the 3 uM primer solution for each reaction, so to be on the safe side , allocate 2 ul of the 3 u M 
primer solution for each sequencing reaction . 
Calculation: amount of primer needed = (# of sequencing reactions using primer) x [ADDRESS_955735] the sequ encing order online through Sequetech’s website 
http://www.sequetech.com/ , making sure to list all your template 
DNAs’ names, primers’ names, the concentration that your primers are 
at (3 uM), and the approximate size of your PCR products. Print out the order form once you have finished and place a copy of it in the bag with your samples.  
5. Schedule a pi[INVESTIGATOR_9696] -up directly fro m your location (make sure that 
everything is ready and scheduled before 3 pm).  
6. You can check results online within [ADDRESS_955736]. Tom Lietman  
48 | Page 
  
13.3 Methods for Resistance Testing 
 
13.3.1 Isolation & Identification of Organisms Using Microbiological Techniques  
Various organisms from nasal, nasopharyngeal, and rectal swabs will be isolated 
using the media and conditions in Table [ADDRESS_955737].  
 
Table 2. Isolation of Organisms from Source - Primary Plating Media & 
Incubating Conditions  
 
Source  Media  Incubation  Organisms Isolated  
 Nasal Swab  Blood and MSA  35°C 
5% CO 2 S. aureus  (core)  
Nasopharyngeal 
Swab  Blood and  Strep 
select plate , 
chocolate, chocolate 
with bacitracin  35°C 
5% CO 2 S. pneumoniae (core)  
H. influenzae  (non -core)  
N. meningitidis  (non -core)   
Recta l Swab  Blood and 
MacConkey  35°C  E. coli (core)  
 
MORDOR Study  
Manual of Operations and Procedures   [CONTACT_73126]  
49 | Page 
 Table 3. I dentification  of Organisms  
 
Organism  Stain  Identification Tests  
S. aureus  
(core)  Gram stain  Catalase and Tube Coagulase or latex 
agglutination reagent  
S. pneumoniae 
(core)  Gram stain  Catalase, O ptochin disc and/or  Desoxycholate 
reagent , alpha -hemolytic on blood agar  
H. influenzae  
(non -core)  Gram stain  Satelliting growth on blood agar , ALA or other 
identification tests  
N. meningitidis  
(non -core)  Gram stain  Sugars utilization or other  identificat ion kit  
S. pyogenes  
(core)  Gram stain  Catalase, beta -hemolytic on blood agar, and 
Bacitracin disc or PYR test  
E. coli  
(core)  Gram stain  Indole , oxidase, beta -hemolytic on blood agar, 
PYR and other identification tests as required  
 
Description of Identif ication Tests:  
We will follow the standard quality control methods already i n place at the 
laboratory. For example, lab staff will perform positive and negative growth 
controls for all media, and positive controls for all stains and identification tests at a pre -determined schedule.  
 
Catalase Test:  
A few drops of 3% hydrogen peroxide are added to colonies removed from agar 
and smeared onto a clean glass slide, and immediately observed for the release of oxygen or “bubbling.” Bubbling is interpreted as the p resence of catalase. Lack of 
bubbling is a negative test.  
 
Tube Coagulase : 
Coagulase plasma is inoculated with an isolated staphylococcal colony and 
incubated for up to 24 hours at 37
°C. Any degree of clot formation is a positive 
reaction and no clot is a negative reaction.  
 
Latex Agglutination:  
A few staphylococcal colonies are mixed with the latex agglutination reagent and 
observed for agglutination. A positive reaction is agglutination of the latex 
particles, while no agglutination is a negative reaction . 
 
Optochin Test:  
An optochin disc is placed onto a blood agar subcultured plate that has been 
inoculated with a pure culture of the test organism. Plates are incubated for [ADDRESS_955738]. Tom Lietman  
50 | Page 
 hours at 35 °C in CO 2. If a zone of inhibition of 14 mm or more is formed, then i t’s 
S. pneumoniae . 
 
Desoxycholate  (10%) Test : 
A drop of reagent is added to a well- isolated colony on a blood agar plate. 
Colonies of S. pneumoniae  will disintegrate after 30 minutes.  
 
Satelliting Growth on Blood Agar : 
Colonies resembling H aemophilus  are s ubcultured to a non -selective b lood agar 
plate and cross streak ed with Coagulase negative S taphylococcu s. Plates are 
incubated in CO [ADDRESS_955739] : 
 
Sugars Utilization Tests:  
 Indole  Test : 
 Oxidase  Test : 
 
PYR Test:  
 
13.3.[ADDRESS_955740] strips (to determine MIC’s) . 
 
Quality Control  
E. coli  ATCC [ZIP_CODE], S. pneumonia e ATCC [ZIP_CODE], H. in fluenzae  ATCC [ZIP_CODE], S. 
aureus ATCC [ADDRESS_955741]. T he suspension is used to inoculate  the appropriate 
susceptibility agar plate for confluent growth. The plate is allowed to dry. 
Antimicrobial disks are placed on the agar plates with sterile forceps or tweezers ; 
disks may not be moved once they have touche d the plates. After the disks are 
placed on the plate, the plates are invert ed and incubate d at 35°C for 16 to 18 
hours. After incubation, the diameter of the zones of complete inhibition (including the diameter of the disk ) (Figure 2) are measured and rec orded in 
millimeters. The measurements can be made with a ruler or sliding caliper on the 
MORDOR Study  
Manual of Operations and Procedures   [CONTACT_73126]  
51 | Page 
 undersurface of the plate without opening the lid. The zones of growth inhibition 
will be compared with the zone -size interpretative table and recorded as 
susceptible , intermediate, or resistant to each drug tested according to CLSI 
guidelines  (see Appendix) . 
 
 
Figure 2. Results of the disk diffusion assay. This Shigella  isolate is  resistant to 
trimethoprim -sulfamethoxazole and is growing up to the  disk (SXT), the zone of 
which is recorded as [ADDRESS_955742] strips . 
In addition, azithromycin  Minimum Inhibitory Concentrations (MIC) are 
determined using E- test strips . A suspension of the isolate is prepared and 
turbidity adjusted until it reaches the  0.[ADDRESS_955743] strips are placed on the agar plates with sterile 
forceps or tweezers ; strips may not be moved once they have touched the plates. 
After the strips  are placed on the plate, the plates are invert ed and incubate d at 
35°C for 20 to 24 hours.  The MIC is read where the ellipse intersects the MIC 
scale on the strip. The MIC  will be compared with the interpretative table 
accordin g to CLSI guidelines  (see Appendix) .  
 
MORDOR Study  
Manual of Operations and Procedures   [CONTACT_73126]  
52 | Page 
 Table 4. Antibiotics Testing Guidelines  
 
Specimen  Organism  Antibiotics T ested  
Nasal  S. aureus  Azithromycin, cefoxitin  
Nasopharyngeal  S. pneumoniae  
H. influenzae  
N. meningitidis  Azithromycin, clindamycin, penicilli n 
(Note: S. pneumonia e - [ADDRESS_955744] penicillin resistance for Kirby [CONTACT_73098])   
Stool  E. coli  Azithromycin, ampi[INVESTIGATOR_10312], co -trimoxazole  
 
Mater ials Required for Susceptibility Testing:  
• MH w/ 5% sheep blood plates  
• MHA plates  
• MH broth or ster ile 0.85% saline 
• Sterile cotton -tipped swabs  
• 0.[ADDRESS_955745] 
• Blood and chocolate plates  
• Caliper for reading zones  
• Forceps  
• Light source  
• Vortex  
• 35°C ambient air and 35°C CO 2 incubator  
 
13.3.3 Nucleic Acid Based Resistance Testing for Stool Specimens  
Stool  specimens not cultured will undergo nucleic acid based resistance testing. 
DNA from the stool samples will be extracted using  some type of  DNA isolation 
kit (i.e. Norgen Stool DNA Isolation Kit) and  the appropriate corresponding  
protocol.[ADDRESS_955746] genes associated with E. coli and antibiotic resistance  
(specifically macrolide resistance) . 
 
MORDOR Study  
Manual of Operations and Procedures   [CONTACT_73126]  
53 | Page 
 Extracting  DNA from Stool Procedure  
1. Lysate Preparation  
a. Mix the sample well to make sure that the stool/preservative mixture is homogenous. Carefully 
remove the lid from the collection tube and aliquot 200 μl of the stool/preservative liquid and add it to 
a Bead Tube provided with the kit (it may be easier to use a pi[INVESTIGATOR_703824] a large orifice pi[INVESTIGATOR_703825]).  
b. Add Lysis Solution  to the Bead Tube, so that the final volume is 1 ml (for our purposes, add 800 μl of 
Lysis Solution). Vortex and centrifuge briefly.  
c. Add 100 μl of Lysis Additive and vortex briefly.  
d. Secure the Bead Tube horizontally on a flat -bed vortex pad with tape, or secure the tube in any 
commercially available bead beater equipment (e.g. Scientific Industries’ Disruptor Genie TM). Vortex 
for 3 minute at maximum speed.  
e. Centrifuge the tube for 2 minutes at [ZIP_CODE] × g (~14,000 RPM) . 
f. Transfer up to 600 μl of supernatant to a DNAase -free microcentrifuge tube (not provided).  
g. Add 200 μl of Binding Solution, mix by [CONTACT_99977]  a few times, and incubate for 1 0 minutes on 
ice. 
h. Spin the lysate for 2 minutes to pellet any cell debris.  
i. Using a pi[INVESTIGATOR_8459], transfer up to 700 μl of supernatant (avoid contact[CONTACT_703842][INVESTIGATOR_703825]) into a 
2 ml DNAase -free microcentrifuge tube (not provided).  
j. Add an equal volume of 70% ethanol (provided by [CONTACT_28024]) to the lysate collected above (100 μl of 
ethanol is added to every 100 μl of lysate). Vortex to mix.  
 2. Binding to Column  
a. Assemble a spin column with one of the provided collection tubes.  
b. Apply 600 μL of the clar ified lysate with ethanol onto the column and centrifuge for 1 minute at [ZIP_CODE] 
× g (~14,000 RPM). Discard the flow through and reassemble the spin column with the collection tube.  
Note:  Ensure the entire lysate volume has passed through into the collection  tube by [CONTACT_703843]. If the entire lysate volume has not passed, spin for an additional minute.  
c. Repeat step 2b with the remaining volume of lysate mixture.  
 
3. Column Wash  
a. Apply 500 μL of Wash Solution I  to the column and centrifuge for 1 minute.  
Note: Ensure the entire wash solution has passed through into the collection tube by [CONTACT_703843]. If the entire wash volume has not passed, spin for an additional minute.  
b. Discard the flow through and reassemble the spin column with its collection tube.  
c. Apply [ADDRESS_955747] the column into a fresh 1.7 mL Elution tube provided with the kit.  
b. Add 50 μL of Elution Buffer  to the column.  
c. Centrifuge for 2 minutes at 200 x g (~2,000 RPM), followed by a 1 minute spin at 14,000 x g (~14,000 RPM ). Note the volume eluted from the column. If the entire volume has not been eluted, spin the 
column at 14,000 x g (~14,000 RPM) for 1 additional minute.  
d. (Optional): An additional elution may be performed if desired by [CONTACT_232843] 4b and 4c using 50 μL of Elution Buffer. The total yield can be improved by [CONTACT_33018] 20 -30% when this second 
elution is performed.  
 
5. Storage of DNA  
The purified genomic DNA can be stored at 2 -8°C for a few days. For longer term storage, -20°C is 
recommended.  
 
  
MORDOR Study  
Manual of Operations and Procedures   [CONTACT_73126]  
54 | Page 
 Amplifying Gene Regions  
We will use DNA extracted from stool specimens and published primers to perform 
PCR reactions for the genes of interest:50-52 
 
Purpose  Genes  
Detecting E. coli  malK  (encodes for malB  
promoter) 53 
 
*This gene will detect for both E. 
coli and Shigella  since the two are 
closely related and are difficult to 
discriminate from one another.  
 
Detecting Antibiotic 
Resistance  mph (A, B)  
erm (A, B, C)  
mef (A)  
ere (A, B)  
msr (A)  
 
 
13.[ADDRESS_955748] recent trachoma 
studies ([COMPANY_002] AMPLICOR).
54,55  
 
13.4.2 Processing of Samples for PCR  
Samples are handled as per Abbott RealTi me sample processing protocol, with 
the following modifications:  
1. Samples are boiled for 10 minutes at 100°C.  Boiling of samples is an 
accepted treatment method to remove substances that may be inhibitory 
to the PCR amplification process  
2. Samples are pooled.  
 
13.4.[ADDRESS_955749]. Tom Lietman  
55 | Page 
 identificat ion number, thus masking the lab until all the samples have been 
processed. The Database Manager will then link the lab ID number to the 
random sample number to reveal the test results by [CONTACT_73105] . 
 
13.4.[ADDRESS_955750].
56 We will unpool all positive pools in the 0 -5 year age 
stratum and estimate th e community prevalence of chlamydial infection as the 
proportion of positive swabs. We will estimate the community prevalence of infection in the 6 -9 and ≥10 year age strata using maximum likelihood 
estimation, similar to our previous trials: the number of  individual swabs with 
the maximum likelihood of having resulted in the observed pooled results will be chosen as the estimate for that village.
57,58 
 
In order to pool the conjunctival samples in the lab, the microbiology lab staff 
will assign a new pool ID number for every sample, and samples will be stored 
at -80°C freezer until PCR testing (if not processed tha t day).  
 
13.4.5 Quality Control 
1. A C. trachomatis (+) control and a C. trachomatis (-) control (targeting 136 
base pairs of a pumpkin gene) is included in each test run of the Abbott 
RealTi me assay . 
2. To test the effect of sample processing, a known positive sample is  
processed and tested in each test run.  (This control is helpful when testing large numbers of negative samples.)  
3. An internal control intended to identify specimens that contain 
polymerase inhibitor is run routinely on each sample.  The internal control 
helps identify false negative results.  
 
13.4.6 Quantification  
For every 0 -5 year old who tests positive for chlamydia, we will also run PCR for 
the beta actin gene on the same sample, in order to normalize the quantity of 
chlamydial DNA to the amount of the specimen. Quantitative results from the 
Abbott system are given in terms of a decision cycle (DC) number. We will generate a ratio of the DC number of the chlamydial DNA to the DC number of the beta actin gene and use the resulting ratio as the chlamydial load.  
MORDOR Study  
Manual of Operations and Procedures   [CONTACT_73126]  
56 | Page 
  
Chapter 14: Study Medication  
Children aged 1 -60 months on the current  census will be offered weight - or 
height -based, directly observed, oral suspension ( azithromycin or placebo) every 
6 months for 2 years ( as performed in trachoma programs ) at each stud y site . In 
addition to being at least [ADDRESS_955751] 3.8 kg to 
be eligible for treatment. This ensures that mistakenly aged or premature infants 
won't be treated. These infants will be eligible for treatment at the subsequen t 
distribution, approximately 6 months later. The  mortality application  will not 
provide a dose for  children weighing  <3.8 kg. 
 We will monitor  adverse events following mass treatments as described in the 
adverse events section . The treatment and monitorin g schedule for all study 
arms is shown in Table 1.  
14.1 Study Medication Description (from [COMPANY_007], Inc.) 
 
Azithromycin  
Zithromax® for oral suspension is supplied in bottles containing azithromycin 
dehydrate powder equivalent to 1200mg per bottle and the f ollowing inactive 
ingredients: sucrose; tribasic  anhydrous sodium phosphate ; hydroxypropyl 
cellulose; xanthan gum; FD&C Red #40; and flavoring including spray dried artificial cherry, crème de vanilla , and banana.  After constitution, a 5mL 
suspension con tains 200mg of azithromycin.  
 
14.1 Dosage Information  
Azithromycin  and placebo  will be administered as a single dose, in oral 
suspension form for children. Dosing will follow the WHO recommendations for 
treatment of active trachoma:  
• Single dose of 20mg/kg in ch ildren (up to the maximum adult dose of 
1g)  
• Height -based dosing of children ( this dosing method is supported by 
[CONTACT_14300] ) 
 
Individuals who are allergic to macrolides/azalides will not be treated.  
 
14.2 Medication Procurement/Donation  
Azithromycin (Zithromax® ) and the placebo have been donated by [CONTACT_703844].  There will be no costs to acquiring the study medication.  [COMPANY_007], 
Inc. will ship azithromycin and placebo directly to the study sites.  
MORDOR Study  
Manual of Operations and Procedures   [CONTACT_73126]  
57 | Page 
 Representatives of each study site  will manage the customs process and 
transport the medication from the port to storage site s.   
 
14.[ADDRESS_955752] the study 
med ication expir ation  dates.  The expi[INVESTIGATOR_703826].  
 
14.4 Antibiotic Distribution & Monitoring Coverage  
After the MORDOR 0  census and monitoring/ collection is complete, treatment 
(azithromycin and placebo) will be administered to all eligible community 
members per study protocol. T eams will participate in training exercises 
regarding drug/placebo distribution and recording techniques  prior to each 
treatment cycle . Training will be in accordance with the Zithromax Program 
Manager’s Guide from the International Trachoma Initiative.    
 
During mass drug administration, distribution team members will use tablet 
computers equipped with an electronic data  capture system to seek out each 
eligible child on the census, administer antibiotic or placebo, and record whether 
or not each person has been treated.  The distribution team will document 
individual reasons for not being treated (e.g. death, temporary ab sence, 
permanent migration, refusal of treatment, etc.). C onsumption of medication will 
be directly observed and t he dose distributed will be documented in the 
electronic data capture system . 
 
We will estimate antibiotic coverage from the most recent biann ual census 
records , aiming for treatment of 80% of children . At the end of each treatment 
round, the UCSF DCC will identify any children who have missed [ADDRESS_955753] this information to the site study coordinator . Census te ams will discern  the reason for missing treatments  
(including unrecorded death) at the next scheduled census . This system will 
serve as a quality control mechanism to reduce the number of false negative deaths in the study.  
 
14.5 Adverse Reactions/Side Effects 
Azithromycin is generally well- tolerated.  The most common side effects of 
azithromycin are diarrhea, nausea, abdominal pain, and vomiting, each of which 
may occur in fewer than one in twenty per sons who receive azithromycin. Rarer 
side effects include abn ormal liver function tests, allergic reactions, and 
nervousness.  Diarrhea due to Clostridium difficile  has been  reported in rare cases.  
MORDOR Study  
Manual of Operations and Procedures   [CONTACT_73126]  
58 | Page 
  
During the consent process, t he common adverse reactions that may occur will 
be explained to parent s/guardians and they will be advised to communicate 
adverse events  to local program representatives immediately. If, for any reason, 
the participant  needs further care, they will be referred to the nearest health 
center for examination and treatment.  
 The trial sites will b e masked to outcomes, so the responsibility for monitoring 
interim analysis will fall on the DSMC. Statistical monitoring is discussed in the Statistical Analysis Plan.  The D ata S afety and Monitoring C ommittee (DSMC) 
will be given authority to discontinue treatments at any time if there is evidence of unexpected harm.   
14.[ADDRESS_955754] for 
this study , and these  monitoring activities will specifically include (but will not 
be limited to) treated [ADDRESS_955755], during 
each follow -up census  we will ask the guardians of  all 7-12 month- old children  in 
all study communities  (both mortality and morbidity) , whether their  children 
had an adverse event after the previous mass medication  distribution. This will 
allow assessment of adverse events from medication distribution among the individuals  aged [ADDRESS_955756] to 
recall bias, so we will also  perform a house -to-house survey  (described below).  
 
MORDOR Study  
Manual of Operations and Procedures   [CONTACT_73126]  
59 | Page 
 Infant  Adverse Events Survey  
To identify any adverse events associated with mass treatment, the UCSF DCC 
will randomly select 30 study communities (15 azithromycin and 15 control communities) to  participate in an adverse events survey. This survey will be 
performed by [CONTACT_73107], approximately 2 
weeks after a mass medication distribution. During the survey, adverse events 
will be elicited only for study participant s aged 1 -6 months at the previous 
census. A structured questionnaire will be performed to elicit dangerous side effects, followed by [CONTACT_3440] -ended question. Specifically, we will ask the 
primary caregiver about the following symptoms during the time since the previous antibiotic distribution: abdominal pain, vomiting, nausea, diarrhea, dyspepsia, constipation, hemorrhoids or rash. To elicit symptoms of serious 
infantile hypertrophic pyloric stenosis which has been reported in rare occasions 
with macrolide u se, census workers will be trained to ask about projectile 
vomiting and feeding problems.  
 
Training  
The household survey team will be the same individuals who conducted the 
census. They will be trained in survey administration methods, including:  
1. Obtaining  informed consent  
2. Accurately selecting the appropriate households to interview   
3. Remaining neutral when asking questions (i.e. asking the question exactly as it is written on the paper in a neutral tone of voice, so as not 
to lead the respondent or introdu ce bias)  
 
Serious Adverse Events  
Any serious adverse events (SAE) will be reported to [COMPANY_007]. An IIR SAE Form 
(Investigator -Initiated Research Serious Adverse Events Form ) will be completed for 
each event.  (See Appendix for form and complete instructions. ) 
 According to [COMPANY_007], an SAE is any adverse event that:  
• Results in death  
• Is life -threatening (i.e., causes an immediate risk of death) 
• Requires inpatient hospi[INVESTIGATOR_1081]  
• Results in persistent or significant disability or incapacity  
• Results in a congenital anomaly or birth defect 
  Or that is considered to be:  
 
• An important medical event  
 
MORDOR Study  
Manual of Operations and Procedures   [CONTACT_73126]  
60 | Page 
 All community residents will be advised to alert a village health worker if they 
experience, within one week of mass treatment, a serious adverse event (by [CONTACT_703845]). An SAE report must be submitted for all deaths in the 
study – regardless of the time of treatment. The local health worker will report to the on -site study coordinator; who must, within 24 hours, su bmit a [COMPANY_007] IIR 
SAE Form  to [EMAIL_1403]
. TL will review, and forward to [COMPANY_007] 
and/or the Medical Monitor, as appropriate.  SAEs must be submitted to [COMPANY_007] 
within [ADDRESS_955757] SAE 
to DSMC if meets criteria of being possibly related to study drug.  
 
Deaths that are reported to the study team outside of the biannual census 
(primary outcome) will be reported as an SAE to [COMPANY_007]. Note that deaths identified via the biannual census, which constitute the primary outcome, will not be reported as SAEs. Deaths that are reported to the study team as part of the 
biannual census will be reported to [COMPANY_007] in aggregate, not by [INVESTIGATOR_216], on a 
quarterly basis.  
14.6.3 Advers e Events D ata 
We will keep records and report all adverse events of azithromycin to the DSMC.  
We will report both efficacy and side effects  of azithromycin separately for the 1 - 
6 month old age group. For any “sudden deaths” believed to be associated with  
azithromycin treatment, key informants will immediately notify the verbal 
autopsy interviewer  via SMS message or another appropriate form of  rapid 
communication.  
 
14.[ADDRESS_955758] should be sent  to 
[EMAIL_1404]
 to request a replacement for the community in question. 
This is not blanket permission to substitute one letter for another – if there are 
several communities for which the assigned treatme nt has run out, a separate 
request must be made for each community.  
 The study site coordinator will make the request; TCP will determine the 
replacement letter, a member of the DCC ( TCP, KR , or ZZ) will make the 
change (s) in the database.  
 The field team  must log out of the MORDOR mobile app and log in again for the 
changes to take effect on the front end. The replacement treatment letter will then 
appear in the app.  
MORDOR Study  
Manual of Operations and Procedures   [CONTACT_73126]  
61 | Page 
 Chapter 15: Protection of Human Subjects  
Before the study begins, each site will obtain  formal ethical approval from their 
respective national ethics committee. In addition, local staff will approach 
community leaders to describe the study and answer any questions . Study staff 
will proceed only if local leadership consents to participate. At  the individual 
level, we will obtain verbal consent from a parent or guardian for all study activities with patient contact, including censuses, examinations, and treatments.  
 
Verbal consent is the best  way to obtain consent, due to the high illiteracy r ates in 
each study area. Children will be included in the study only following the receipt 
of consent from a parent or guardian. If, at any time, a parent or guardian elects to withdraw a family member from the study, they will be free to do so. 
Individuals who withdraw will be offered the same medical treatment outside 
the study.  
 Children with wasting, stunting, malaria, or anemia will be referred for 
appropriate treatment by [CONTACT_7355], at the nearest health center.  
 
15.[ADDRESS_955759] Approval  
  
15.1.1.  Niger  
 UCSF Committee on Human Research 
UCSF’s  Committee on Human Research will annually review study protocol for 
ethical approval.  
 
Emory University I nstitutional Review Board  
The Emory University Institutional Review Board will annually re view study 
protocol for ethical approval.  
 
Comité d’Ethique du Niger    
The study protocol will be reviewed and granted ethical approval by [CONTACT_73109]é 
d’Ethique du Niger  before any patient -related research activities begin.  
MORDOR Study  
Manual of Operations and Procedures   [CONTACT_73126]  
62 | Page 
  
15.1.[ADDRESS_955760]    
The study protocol will be reviewed and granted ethical approval by [CONTACT_703846] -related research activities begin.  
 
15.1.3 Malawi 
 
London School of Hygiene & Tropi[INVESTIGATOR_703827] & Tropi[INVESTIGATOR_703828].  
 
Malawi IRB  
The study protocol will be reviewed and granted ethical approval by [CONTACT_703847] -related research activities 
begin.     
 
15.[ADDRESS_955761], t he chairman of each village  will be asked for permission to include the 
village  in the study.  Additionally, the study will be discussed with all adult s in 
the village  by [CONTACT_73112] (s). 
  
Informed consent scripts will b e translated into local languages before the study  
can begin . Consent scripts will then be back -translated by a different party to 
ensure comprehension.  Consent scripts will be submitted and approved by 
[CONTACT_73113], Niger,  and  Tanzani a prior to study 
implementation. Then they will be read aloud to each study participant (and his/her parent/guardian) by a local team member who is a native speaker of the 
local language to ensure that they understand the risks and benefits of 
participatin g in all study activities . Young adults and children under  [ADDRESS_955762]. Tom Lietman  
63 | Page 
 15.[ADDRESS_955763] 
to ensure that th e parent /guardian of the child understands the process of 
assessing anthropometric measurements.   The examiners will attempt to 
minimize discomfort for all study participants before, during, and after the 
measurements are taken. Children with wasting, stun ting, malaria, or anemia 
will be referred for appropriate treatment  at the nearest health center.  
MORDOR Study  
Manual of Operations and Procedures   [CONTACT_73126]  
64 | Page 
 Chapter 16: Study Monitoring  
The UCSF team will conduct annual monitoring visits to project sites in Malawi 
and Tanzania. The LSHTM team will conduct annual  visits to Niger. Annual site 
visits will ensure uniform data collection , as well as adequate training and 
certification.  
Chapter 17: Data and Safety Monitoring Committee  Charter  
This Charter is for the Data Safety and Monitoring Committee (DSMC) for 
Mortality Reduction after Oral Azithromycin (MORDOR): OPP1032340.[ADDRESS_955764] of the trial. The DSMC will provide recommendations about stoppi[INVESTIGATOR_30902]. To contribute to the 
integrity of the trial, the DSMC may also formulate recommendations relating to 
the selection/recruitment/retention of participants, to protocol -specified 
regimens, and the procedures for data management and quality control.  
 
The DSMC will be advisory to the trial leadership group, hereafter referred to as the Steering Committee (SC). The SC will be responsible for promptly reviewing the DSMC recommendations  and determining , whether to continue or terminate 
the trial, and to determine whether amendments to the protocol are required.  If 
needed, the DSMC may seek the advice of a content expert outside of the committee.  
MORDOR Study  
Manual of Operations and Procedures   [CONTACT_73126]  
65 | Page 
  
17.[ADDRESS_955765] and monitoring of randomized clinical trials  including subsaharan Africa . 
 
Judd Walson, MD, MPH (Chair): pediatrics and global health  
Alan Hightower, MS: biostatistics  
Latha Rajan, MD, MPH&TM: global health Emily Anderson, PhD, MPH: bioethics  
Wondu Alemayehu, MD, MPH: global health 
 
17.[ADDRESS_955766] 
research organization s (CRO) , or with other sponsors having products that are 
being evaluated or that are competitive with those in the trial. The DSMC will be 
responsible for deciding whether these consulting agreements or financial 
interests materially impact their objectivity.  
 
The DSMC members will be responsible for advis ing fellow members of any 
changes in any of the membership requirements that occur during the course of 
the trial. It may be appropriate for DSMC members who develop significant 
conflicts of interest resign from the DSMC.   DSMC membership is to be for the  full duration of the trial. If any members leave 
the DSMC , the SC, in consultation with the DSMC , will promptly appoint a 
replacement.    
 
17.[ADDRESS_955767]. Tom Lietman  
66 | Page 
 the standard operating procedures and to discuss the format and content of the 
Open and Closed Reports that will be used to present trial results . 
 The Organizational Meeting will be attended by [CONTACT_703848] , lead trial 
investigators, and the trial biostatistician. The DSMC will be given the drafts of the trial protocol,  the Statistical Analysis Plan, the DSMC Charter, and the 
current version of the case report forms. At subsequent meetings, committee members  will receive Open and Closed Data Reports.  
 
Formal Interim Analysis Meetings  
One or more ‘Formal Interim Analysis’  meetings will be held to review data 
relating to treatment safety and efficacy, and quality of trial conduct. There will 
be at least two interim decisions to be made by [CONTACT_6802], at approximately 12 
months and 24 months into the study.  
 
17.5 Procedures to Ensure Confidentiality and Proper Communication  
To enhance the integrity and credibility of the trial, procedures will be 
implemented to ensure the DSMC has access to all emerging information from the trial regarding comparative results of efficacy and safety,  aggregated by 
[CONTACT_2939].  
 
Closed Sessions  
Sessions involving only DSMC members and, where appropriate, those 
unmasked trial investigators (on the Data Coordinating Committee) who generate the Closed Reports (called Closed Sessions) will be held to allow 
discussion of confidential data from the trial, including information about the 
relative efficacy and safety of interventions.  
 At a final Closed Session, the DSMC will develop a consensus on its list of 
recommendations, including that relating to whether the trial should continue.  
 
Open Session  
In order for the DSMC to have access to information provided, by [CONTACT_83671], or members of regulatory authorities, a joint session between these 
individuals and DSMC members will be held between the C losed Sessions.  
 
Open and Closed Reports  
For each DSMC meeting, Open and Closed Reports will be provided. Open 
Reports, will include data on recruitment and baseline characteristics, pooled data on eligibility violations, and completeness of follow -up and  compliance. The 
study statistician (TCP) will prepare these Open Reports.  
 
MORDOR Study  
Manual of Operations and Procedures   [CONTACT_73126]  
67 | Page 
 Closed reports, available only to those attending the Closed Sessions of the 
meeting, will include analyses of primary and secondary efficacy endpoints, 
including subgroup and adj usted analyses, AEs and symptom severity, , and 
Open Report analyses that are displayed by [CONTACT_65237]. These Closed 
Reports will be prepared by [CONTACT_703849].  
 
The Open and Closed Reports should provide information that is accurate, with 
follow -up that is  complete to within two months of the date of the DSMC 
meeting. The Reports should be provided to DSMC members approximately three days prior to the date of the meeting.  
 
Minutes of the DSMC Meeting 
The research team will prepare minutes for the open portion of the meeting, 
including the DSMC’s recommendations.  
 
Recommendations to the Steering Committee (SC)  
At each meeting of the DSMC during the trial, the committee  will make a 
recommendation to the Steering Committee to continue or ter minate. This 
recommendation will be based primarily on safety and efficacy considerations 
and will be guided by [CONTACT_73115].  
 
Recommendations to amend the protocol or conduct of the study made by [CONTACT_73116]. The SC will be 
responsible for deciding whether to continue or to stop the trial based on the 
DSMC recommendations.  
 
The DSMC will be notified of all changes to the protocol or to study conduct. The 
DSMC c oncurrence will be sought on all substantive recommendations or 
changes to the protocol or study conduct prior to implementation.  
 
The SC may communicate information in the Open Report to the sponsor  and 
may inform them of the DSMC recommended alterations  to study conduct or 
early trial termination in instances in which the SC has reached a final decision 
agreeing with the recommendation. The SC will maintain confidentiality of all 
information it receives other than that contained in the Open Reports until  after 
the trial is completed or until a decision for early termination has been made.  
 
17.6 Statistical Monitoring Guidelines  
The SC will propose statistical rules for a futility stoppi[INVESTIGATOR_1877] (requested by [CONTACT_103]) and an efficacy stoppi[INVESTIGATOR_703829]. A decision will 
be made whether the efficacy stoppi[INVESTIGATOR_73061], 2-year study.  
MORDOR Study  
Manual of Operations and Procedures   [CONTACT_73126]  
68 | Page 
  
17.[ADDRESS_955768] Information  
 
Table 5: DSMC Contact [CONTACT_703850] x 6307 
Addis Ababa 
Ethiopia 
[PHONE_1762] 42  
walemayehu@berhan -health.org 
Emily Anderson  
Assistant [CONTACT_703854]  
[ADDRESS_955769]. 
Maywood, IL [ZIP_CODE]  
[PHONE_1755]  
[EMAIL_1406] 
Allen Hightower  
Statist ician 
[ADDRESS_955770]  
Atlanta, GA [ZIP_CODE]  
[PHONE_1756]  
[EMAIL_1407]  
Latha Rajan  
Clinical Associate Professor  
[ADDRESS_955771]  
Department of Tropi[INVESTIGATOR_703830], LA [ZIP_CODE]  
[PHONE_1757]  
[EMAIL_1408]  
Judd Walson, Chair  
Associate [CONTACT_40758] of Washington 
Box [ADDRESS_955772]  
Seattle, WA [ZIP_CODE]  
[PHONE_1758] (office)  
[PHONE_1759] (mobile)  
[EMAIL_1409]  
MORDOR Study  
Manual of Operations and Procedures   [CONTACT_73126]  
69 | Page 
 Chapter 18: Data Collection , Man agement , and Security  
 
18.1. Scope of Data  
Mortality and morbidity data from Malawi, Niger, and Tanzania will be collected in 
this trial. Mortality data includes: census, mortality, and treatment. Morbidity and 
resistance data includes the following: census, mor tality, treatment, and morbidity 
assessments. Costing data will also be collected, including the costs of azithromycin, antibiotic distributors, supervisors, drivers, fuel, an d time of community volunteers.  
Mortality Study  
Trained census workers will collect census data on all households in the study sites (name, birthdate, age, gender of all household members) and keep track of births, deaths, and migration of children eligible for treatment. In addition to biannual census updates, trained community health  workers and study supervisors will 
conduct WHO verbal autopsy interviews through the duration of the study to provide information on the cause of death. Trained distribution teams will collect data on treatment status and dose given to all study participa nts, if treatment is 
provided apart from the time of census .    
 
Morbidity Study  
Census, mortality, and treatment data collection procedures will be identical to the 
mortality study. In addition, trained health workers will collect data on core morbidity a ssessments such as blood samples (thick smears and dried blood spots 
for malaria, microcuvettes for hemoglobin), stool samples, nasal swabs,  and 
nasopharyngeal swabs. Note that for de -identification  purposes a random number 
sticker will be affixed to each specimen collected. In addition, before sample 
collection, parents or guardians will be asked a standardized series of questions to determine whether the child has had recent fever, cough, or diarrhea. Clinic -based 
case finding  will be conducted at local health clinics, which will involve transcription 
of health records.  
 Certain morbidity assessments will be entered into handheld mobile devices at the time of the examination (e.g. hemoglobin, responses to symptom questionnaire), while lab results for thic k smears, dried blood spots, nasal, nasopharyngeal, and stool 
specimens will be entered after confirmation.  
18.[ADDRESS_955773]. Tom Lietman  
70 | Page 
 nearly real-t ime monitoring of activity at the study site. Each study site will have 
a local data coordinating center within the study area. All handheld devices and 
data entry coordinating centers will be password protected, and all changes in 
data will be noted, including the date of the change, and the person who made the change. To ensure the quality of the data, we will conduct training sessions before each biannual census  where needed . The central database application will 
use hard disk encryption and physical protection of the server (which is to be maintained in a locked room accessible only to authorized personnel). The database will be based on mySQL (which supports standard SQL queries). Data will be backed up off site (providing integrity in case of the physical loss of the 
server). Data will never be deleted from mobile capture devices until at least one 
offsite backup has been completed. Data security during electronic transfer will be achieved through use of the Advanced Encryption Standard (AES).  
 
18.3 Data Monitoring  and Cleaning  
Data monitoring and cleaning will be overseen by [CONTACT_66568] 
(DCC) at the coord inating site. Data collection will be monitored on a weekly 
basis by [CONTACT_73118]. 
The Salesforce dashboard will consist of the following reports by [CONTACT_3885]: Date Household Census Completed, Numbe r of Households Census Completed by 
[CONTACT_73119], Percent Household Census Completed by [CONTACT_73105], Treatment Status by [CONTACT_73120], Age Distribution by [CONTACT_73120], Sex Distribution by [CONTACT_73120], GPS Missing by [CONTACT_73120], GPS Missing by [CONTACT_73119], Number of Records Synced by [CONTACT_1782],  
Assigned Treatment by [CONTACT_73121], Treatment Status by [CONTACT_31365], Treatment 
Status by [CONTACT_73119], Age Distribution by [CONTACT_73119], and Sex Distribution by [CONTACT_73119].  
 
The DCC will ensure that the site study coordinators log on to Salesforce weekly 
to confirm the sta tus of the dashboard. In addition, upon each village census 
completion, the DCC will create and maintain a STATA program to identify data 
quality concerns. Any such concerns which must be addressed at the site specific level will be queried by [CONTACT_15791]. At every phase , as each village is completed 
and the data is considered cleaned, the data will be locked and a list of deaths will be generated and provided to each site for verbal autopsy.  
 
References  
 
1. Rajaratnam JK, Marcus JR, Flaxman AD, et al. Neonatal, postneonatal, 
childhood, and under-5 mortality for 187 countries, 1970-2010: a systematic analysis of 
progress towards Millennium Development Goal 4. Lancet 2010;375:1988-2008. 
MORDOR Study  
Manual of Operations and Procedures   [CONTACT_73126]  
71 | Page 
 2. Porco TC, Gebre T, Ayele B, et al. Effect of mass dis tribution of azithromycin for 
trachoma control on overall mortality in Ethiopi[INVESTIGATOR_73063]: a randomized trial. JAMA : 
the journal of the American Medical Association 2009;302:962-8. 3. Shaikh S, Schulze KJ, Kurpad A, et al. Development of bioelectrical impedance analysis -based equations for estimation of body composition in postpartum rural 
Bangladeshi women. The British journal of nutrition 2012:1-9. 4. Waage J, Banerji R, Campbell O, et al. The Millennium Development Goals: a 
cross -sectoral analysis and p rinciples for goal setting after 2015 Lancet and London 
International Development Centre Commission. Lancet 2010;376:991-1023. 5. You D, Wardlaw T, Salama P, Jones G. Levels and trends in under- 5 mortality, 
1990-2008. Lancet 2010;375:100-3. 6. Bhutta ZA, Chopra M, Axelson H, et al. Countdown to 2015 decade report (2000-10): taking stock of maternal, newborn, and child survival. Lancet 2010;375:2032-44. 7. Black RE, Cousens S, Johnson HL, et al. Global, regional, and national causes of child mortality in 200 8: a systematic analysis. Lancet 2010;375:1969-87. 
8. Arifeen SE, Hoque DM, Akter T, et al. Effect of the Integrated Management of Childhood Illness strategy on childhood mortality and nutrition in a rural area in Bangladesh: a cluster randomised trial. Lancet 2009;374:393-403. 9. Sazawal S, Black RE. Effect of pneumonia case management on mortality in 
neonates, infants, and preschool children: a meta-analysis of community-based trials. Lancet Infect Dis 2003;3:547-56. 10. Moonen B, Cohen JM, Snow RW, et al . Operational strategies to achieve and 
maintain malaria elimination. Lancet 2010;376:1592-603. 11. Solomon A, Zondervan M, Kuper H, Buchan J, Mabey D, Foster A. Trachoma control: a guide for programme managers. Geneva: World Health Organization; 2006. 12. Melese M, Alemayehu W, Lakew T, et al. Comparison of annual and biannual mass antibiotic administration for elimination of infectious trachoma. JAMA 2008;299:778-84. 13. Lietman T, Porco T, Dawson C, Blower S. Global elimination of trachoma: how frequently should we administer mass chemotherapy? Nat Med 1999;5:572-6. 14. Schachter J, West SK, Mabey D, et al. Azithromycin in control of trachoma. Lancet 1999;354:630-5. 15. Bailey RL, Arullendran P, Whittle HC, Mabey DC. Randomised controlled trial of single-dose azithromycin in treatment of trachoma. Lancet 1993;342:453-6. 16. Coles CL, Seidman JC, Levens J, Mkocha H, Munoz B, West S. Association of mass treatment with azithromycin in trachoma -endemic communities with short- term 
reduced risk of diarrhea in young children. The American journal of tropi[INVESTIGATOR_40667] 2011;85:691-6. 17. Lode H, Borner K, Koeppe P, Schaberg T. Azithromycin-- review of key 
chemical, pharmacokinetic and microbiological features. The Journal of antimicrobial chemotherapy 1996;[ADDRESS_955774] C:1-8. 18. Miller GY, Algozin, K. A., McNamara, P. E. and Bush, E. J,. Productivity and economic impacts of feed -grade antibiotic use in pork production. J Agr Appl Econ 
2003;12:469-82. 
MORDOR Study  
Manual of Operations and Procedures   [CONTACT_73126]  
72 | Page 
 19. Fry AM, Jha HC, Lietman TM, et al. Adverse and benefici al secondary effects of 
mass treatment with azithromycin to eliminate blindness due to trachoma in Nepal. Clin 
Infect Dis 2002;35:395-402. 20. Sadiq ST, Glasgow KW, Drakeley CJ, et al. Effects of azithromycin on malariometric indices in The Gambia. Lancet 1995;346:881-2. 
21. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 2006;367:1747-57. 22. Chidambaram JD, Melese M, Alemayehu W, et al. Mass antibiotic treatment and 
community protection in trachoma control programs. Clin Infect Dis 2004;39:e95-7. 23. House JI, Ayele B, Porco TC, et al. Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster -randomised trial. Lancet 
2009;373:1111-8. 24. Goossens H, Ferech M, Vander Stichele R, Elseviers M. Outpatient antibiotic use in Europe and association with resistance: a cross -national database study. Lancet 
2005;365:579-87. 25. Pi[INVESTIGATOR_73064] M, Kotilain en P, Kaurila T, Klaukka T, Palva E, Huovinen P. 
Macrolide-resistant Streptococcus pneumoniae and use of antimicrobial agents. Clin Infect Dis 2001;33:483- 8. 
26. Bronzwaer SL, Cars O, Buchholz U, et al. A European study on the relationship between antimicr obial use and antimicrobial resistance. Emerg Infect Dis 2002;8:278-82. 
27. Hotez PJ, Fenwick A, Savioli L, Molyneux DH. Rescuing the bottom billion through control of neglected tropi[INVESTIGATOR_73065]. Lancet 2009;373:1570-5. 28. Sommer A, Tarwotjo I, Djunaedi E, et al. Impact of vitamin A supplementation on childhood mortality. A randomised controlled community trial. Lancet 1986;1:1169-73. 29. Rahmathullah L, Underwood BA, Thulasiraj RD, et al. Reduced mortality among children in southern India receiving a small weekly dose of vitamin A. N Engl J Med 1990;323:929-35. 30. Vijayaraghavan K, Radhaiah G, Prakasam BS, Sarma KV, Reddy V. Effect of massive dose vitamin A on morbidity and mortality in Indian children. Lancet 1990;336:1342-5. 31. West KP, Jr., Pokhrel RP, Katz J, et al. Efficacy of vitamin A in reducing preschool child mortality in Nepal. Lancet 1991;338:67-71. 32. Vijayaraghavan K, Radhaiah G, Reddy V. Vitamin A supplementation and childhood mortality. Lancet 1992;340:1358-9. 33. Vitamin A supplementation in northern Ghana: effects on clinic attendances, 
hospi[INVESTIGATOR_614], and child mortality. Ghana VAST Study Team. Lancet 1993;342:7-12. 34. Daulaire NM, Starbuck ES, Houston RM, Church MS, Stukel TA, Pandey MR. Childhood mortality after a high dose of vitamin A in a high risk population. BMJ 1992;304:207-10. 35. Bryce J, Terreri N, Victora CG, et al. Countdown to 2015: tracking intervention coverage for child survival. Lancet 2006;368:1067-76. 
MORDOR Study  
Manual of Operations and Procedures   [CONTACT_73126]  
73 | Page 
 36. Jones G, Steketee RW, Black RE, Bhutta ZA, Morris SS. How many child deaths 
can we prevent this year? Lancet 2003;362:65-71. 37. International Trachoma Initiative: Frequently Asked Questions. (Accessed November 3rd, 2011, at http://trachoma.org/iti-frequently- asked -questions.
) 
38. Fenwick A, Molyneux D, Nantulya V. Achieving the Millennium Development Goals. Lancet 2005;365:1029-30. 39. Verbal Autopsy Standards: Ascertaining and attributing causes of death. 2013. (Accessed March 6th, 2013, 2013, at http://www.who.int/healthinfo/statistics/verbalautopsystandards/en/.
) 
40. Hsiang MS, Lin M, Dokomajilar C, et al. PCR-based pooling of dried blood spots for detectio n of malaria parasites: optimization and application to a cohort of Ugandan 
children. Journal of clinical microbiology 2010;48:3539-43. 41. Sutcliffe J, Grebe T, Tait -Kamradt A, Wondrack L. Detection of erythromycin-
resistant determinants by [CONTACT_954]. Antimicro bial agents and chemotherapy 1996;40:2562-6. 
42. Pai R, Gertz RE, Beall B. Sequential multiplex PCR approach for determining 
capsular serotypes of Streptococcus pneumoniae isolates. Journal of clinical microbiology 2006;44:124-31. 43. Tobias J, Vutukuru SR . Simple and rapid multiplex PCR for identification of the 
main human diarrheagenic Escherichia coli. Microbiol Res 2011. 44. Norgen Biotek Corporation. Stool Nucleic Acid Collection and Transport Tubes Product Insert (PI45650-1). In; 2013. 45. Steenkeste N, Incardona S, Chy S, et al. Towards high-throughput molecular 
detection of Plasmodium: new approaches and molecular markers. Malar J 2009;8:86. 46. Qiagen. TopTaq PCR Handbook 2010. 47. Qiagen. QIAquick Spin Handbook 2008. 48. GE Healthcare. Nucleic Acid  Sample Preparation for Downstream Analyses 
Principles and Methods Handbook.23-9. 49. Norgen Biotek Corporation. Stool DNA Isolation Kit Product Insert (PI27600- 3) 
In; 2009. 50. Phuc Nguyen MC, Woerther PL, Bouvet M, Andremont A, Leclercq R, Canu A. Escherichia coli as reservoir for macrolide resistance genes. Emerg Infect Dis 
2009;15:1648-50. 51. Nakhjavani FA, Emaneini M, Hosseini H, et al. Molecular analysis of typi[INVESTIGATOR_73066] (EPEC) isolated from children with diar rhoea. 
Journal of medical microbiology 2013;62:191-5. 52. Ramotar K, Waldhart B, Church D, Szumski R, Louie TJ. Direct detection of verotoxin-producing Escherichia coli in stool samples by [CONTACT_954]. Journal of clinical microbiology 1995;33:519-24. 53. Wang RF, Cao WW, Cerniglia CE. PCR detection and quantitation of predominant anaerobic bacteria in human and animal fecal samples. Applied and environmental microbiology 1996;62:1242-7. 54. Moller JK, Pedersen LN, Persson K. Comparison of the Abbott RealTime CT new formulation assay with two other commercial assays for detection of wild -type and new 
variant strains of Chlamydia trachomatis. Journal of clinical microbiology 2010;48:440-3. 
MORDOR Study  
Manual of Operations and Procedures   [CONTACT_73126]  
74 | Page 
 55. Cheng A, Qian Q, Kirby [CONTACT_73122]. Evaluation of the Abbott RealTime CT/NG assay in 
comparison to the [COMPANY_002] Cobas Amplicor CT/NG assay. Journal of clinical microbiology 2011;49:1294-300. 56. Morre SA, van Dijk R, Meijer CJ, van den Brule AJ, Kjaer SK, Munk C. Pooling cervical swabs for detection of Chlamydia trachomatis by [CONTACT_954]: sensitivity, dilution, inhibition, and cost-saving aspects. Journal of clinical microbiology 2001;39:2375-6. 57. Diamant J, Benis R, Schachter J, et al. Pooling of Chlamydia laboratory tests to determine the prevalence of ocular Chlamydia trachomatis infection. Ophthalmic 
Epi[INVESTIGATOR_5541] 2001;8:109-17. 58. Gebre T, Ayele B, Zerihun M, et al. Comparison of annual versus twice- yearly 
mass azithromycin treatment for hyperendemic trachoma in Ethiopia: a cluster -
randomised trial. Lancet 2012;379:143-51. 59. Ellenberg SS FT, De Mets DL. Data monitoring committees in clinical trials: A 
practical perspective: John Wiley & Sons, LTD; 2003.  
 
MORDOR Study  
Manual of Operations and Procedures   [CONTACT_73126]  
75 | Page 
 Appendix  
 
Niger  
Malawi 
Tanzania SAP  
Abbreviated Verbal Autopsy Questionnaire  
Infant Adverse Events survey  
Mobile App Manual  
[COMPANY_007] Investig ator Initiated Research Serious Adverse Event Report Form and  
 Completion Guide  
Resistance Breakpoints Table  (to be added)  
Costing Forms  (to be added)  
Data Management Plan (to be added) 
MORDOR Study  
Manual of Operations and Procedures   [CONTACT_73126]  
76 | Page 
 MORDOR MOP Change Log  
Date  Version  Edit  
1 Apr 2015  1.7 Removed ear swabs from morbidity non -core activities  
1 Apr 2015  1.7 Removed symptom questionnaire from morbidity non -
core activities  
1 Apr 2015  1.7 Modification of section 6.1: Census Supervision.  
From:  Once the study coordinator is confident that the entire 
commun ity has been reached, and that the amount of missing 
data are acceptable (defined as <10% of children in a 
community), the study coordinator will “lock” the census data 
collection for that community, and no changes can made be  
made to the census until the next census.  
To: Once the study coordinator is confident that the entire 
community has been reached, and that the amount of missing data are acceptable (defined as <10% of children in a 
community), the study coordinator (or other research team 
member) will certify the census data collection for that 
community complete via Salesforce.  
1 Apr 2015  1.7 Added option to use DNA/RNA shield media by [CONTACT_703851] (Section 9)  
1 Apr 2015  1.7 Added option to use Norgen Stool Preservative for rectal 
swab collection (Section 9)  
1 Apr 2015  1.7 Added details for preparing DNA/RNA shield media 
(section 13.1.2)  
1 Apr 2015  1.7 Added 3.8kg minimum weight requirement for 
treatment (section 14)  
1 Apr 2015  1.7 Added: “Training will be in accordance with the 
Zithromax Program Manager’s Guide from the 
International Trachoma Initiative.” (Section 14.4)  
1 Apr 2015  1.7 Added: “An SAE report must be submitted for all deaths 
in the study – regardless of the time of treatment.” 
(Section 14.6.2)  
8 Sept 2015  1.7 Costing  optional; clarification that dried blood spots are 
optional  
2 June  2016  1.8 Modification of Section 6.3: Verbal Autopsy, 
Questionnaire Administration.  
From:  Our goal is to perform each verbal autopsy within 2 
months of death.  
To: Our goal is to perform each verbal autopsy within 2 
months of identification of death.    
2 June 2016  1.8 Modification of Section 4.3: Study Schedule table.  
From:   Fall, Winter, Spring, and Summer.  
MORDOR Study  
Manual of Operations and Procedures   [CONTACT_73126]  
77 | Page 
 To: Month specific dates i.e. Jan 15 -July 15 for each 
phase.     
2 June 2016  1.8 Modification of Section 4.3: Study Schedule table.  
From:  Malaria Collection occurring between MORDOR 
18 and 24 
To: Malaria Collection as part of MORDOR 6   
2 June 2016  1.8 Added in Section 4.3: Study Schedule table:  
Addition of *: +/ - 1 month    
2 June 201 6 1.8 Modification of Section 4.3: Study Schedule table legend 
narrative.  
From:  …anthropometry from all children aged… 
To: …anthropometry from a cohort of children aged…  
2 June 2016  1.8 Added: “TL will also forward SAE to DSMC if meets 
criteria of being possibly related to study drug.” (Section 
14.6.2)  
2 June 2016  1.8 Added: “paper” to Supplies  
Added: “with pi[INVESTIGATOR_73044].” 
to Note  
(Section 8.2: S et-up drying area for TropBio bloodspots ) 
2 June 2016  1.8 Added Section 18.3 Data Mon itorin g and Cleaning  
27 June 2018  1.9 Clarified how deaths as part of the primary outcome will 
be reported to [COMPANY_007].  
 